Embrace your indy power!

Hear from leaders, influencers, practice owners and powerhouses.

From technology to team building to taking charge of your financials—get inspired.

12 steps to success

...and more tips inside this booklet!

Booklet published by American Animal Hospital Association with a generous educational grant from CareCredit
The budget-friendly payment solution for your beyond-busy days.

At CareCredit, we know how hectic your days can be! We can’t change that. But the CareCredit health and pet care credit card’s flexible payment experience can help ease the way for you and your clients.

TAKE TIME BACK
CareCredit’s self-guided experience lets clients learn all about financing on their own so you can slow down and focus on care.

PROVIDE AN EASY WAY TO PAY
Providers enrolled with CareCredit get a custom link and QR code to help simplify financing. Clients just click or scan to see if they prequalify, apply and pay.

WE HELP LIGHTEN THE LOAD
Prewritten content for texts, emails and social media make it easier to let clients know flexible financing is available as they plan ahead.

GET STARTED TODAY. Call 844-812-8111 to apply to enroll and mention code AAHA1223VA. Or visit carecredit.com/vetenroll to learn more.
Inventory

Pro Tips

5 Ways to Make Inventory Easier 29

2023 AAHA Management of Allergic Skin Diseases in Dogs and Cats Guidelines

Executive Summary of the Latest Guidance from AAHA 36
My Vet Takes Good Care of Me.

Medi-Dose®/EPS® Takes Good Care of My Vet.

With over 50 years of health care experience, Medi-Dose/EPS stocks and supplies a wide and varied line of veterinary pharmacy and nursing accessories to help you care for your patients…large, small and in-between. Please call or e-mail us to order or for more information.

Products and accessories for administering, compounding and dispensing

- Bottles
- Bags
- Trays
- Bins
- Labels
- Tapes
- Solid oral packaging
- Liquid oral packaging
- Oral syringes
- Tamper-evident seals
- Sterile droppers
- So much more

800.523.8966

MediDose.com
Better together

We’re excited to announce that you can now purchase both Shor-Line and Midmark products through your Midmark Authorized Distributor.

Together, we’re bringing you a broader range of animal care solutions that are backed by the same innovation, quality and excellence you expect.

Contact your Midmark Authorized Distributor, or scan the code for more information.
Vol. 39, No. 12
DECEMBER 2023

Trends magazine provides timely perspectives on the art and business of companion animal veterinary practice to all members of the practice team. trends@aaha.org

Editorial Director Ben Williams
Managing Editor Cara Hopkins
Senior Graphic Designer Robin Taylor
Graphic Designer Alison Silverman
Director of Guidelines Ingrid Taylor, DVM
Accreditation Specialist Aimee Potter, RVT
Copywriter Kristen Green Seymour

Advertising
National Sales Manager Stephanie Pates
Advertising and Sales Manager Sean Thomas
Advertising and Sponsorship Specialist Jennifer Beierle

Journal Highlights Abstracts of the current issue of JAAHA, Journal of the American Animal Hospital Association, are reprinted with permission. For masthead information, editorial review board, authors’ guidelines, and subscription information, see the online publication at aaha.org or jaaha.org.

Subscriptions Trends magazine is provided to AAHA members as a member benefit (annual membership dues include $60 for a subscription). Annual nonmember subscriptions: $70. Single copies: $20. To subscribe, call 800-883-6301, email aahal@aaha.org, or visit aaha.org/trends.

RapidHeat™ Sterilization Specifically Designed for Veterinary Clinics and Hospitals. Fast Instrument Turnaround and No More Wet Surgical Packs!

NO WATER • NO DRYING • NO CORROSION • NO MAINTENANCE

The RH-ProVET offers ease of use and maximum flexibility in sterile processing for all veterinary practices, clinics and hospitals.

Postmaster Trends magazine® (ISSN 1062-8266) is published 12 times per year (January, February, March, April, May, June, July, August, September, October, November, December) by the American Animal Hospital Association, at 14142 Denver West Parkway, Suite 245, Lakewood, CO 80401. Periodicals postage paid at Denver, Colorado, and at additional mailing offices. Canadian Post Agreement Number 40044253; send change-of-address information and blocks of undeliverable copies to P.O. Box 1051, Fort Erie, ON L2A 6C7. Printed in the USA. Postmaster: Send address changes to Trends magazine, 14142 Denver West Parkway, Suite 245, Lakewood, CO 80401.

Publication in this magazine of any advertisement, article, product information, or other information or data does not necessarily imply that the American Animal Hospital Association endorses or approves the advertiser, the product, the service, or the authors’ viewpoints. The information presented is intended to help you make good decisions, but it is not a replacement for appropriate financial, legal, or other advice. Neither this publication nor AAHA in any way endorses or guarantees the accuracy, reliability, or completeness of the facts, views, opinions, recommendations, information, or statements contained in this publication. In addition, nothing within these pages should be construed as an offer or solicitation to purchase or sell any investment items. Readers are urged to consult their attorneys, accountants, and other advisors on all practice-related decisions. No part of this issue may be reproduced in any form without written permission from the publisher. The sole exception is made for veterinary practices, which may make a limited number of copies for use within the practices. For all other uses, including all uses by commercial entities, please send your request to permissions@aaha.org. AHA shall not be held liable for adverse reactions to or damage resulting from the application of this information or any misstatement or error contained in this work. AAHA shall be held harmless from any and all claims that may arise as a result of any reliance on the information provided. ©2023 American Animal Hospital Association. All rights reserved.

Cover image: cosinart/iStock via Getty Images Plus
RapidHeat™ Sterilization Specifically Designed for Veterinary Clinics and Hospitals. Fast Instrument Turnaround and No More Wet Surgical Packs!

NO WATER • NO DRYING • NO CORROSION • NO MAINTENANCE

The RH-ProVET offers ease of use and maximum flexibility in sterile processing for all veterinary practices, clinics and hospitals.

© CPAC Equipment, Inc., 2023

NOW upgraded with our new ActivBiome+ Kidney Defense prebiotic blend.

SCIENCE DID THAT.
29 Make Inventory Easier
Manage Inventory Like a Pro
by Nicole Clausen,
CSSGB, CCFP

36 2023 AAHA
Management of Allergic Skin Diseases in Dogs and Cats Guidelines
Executive Summary of the Latest Guidance from AAHA
by Constance Hardesty
42 Money Matters
Profit Checkup: What Are You Missing?
Check in with your numbers and consider making changes for 2024

46 Get Smart
Taking Stock for the New Year
What you should be stocking in your pharmacy for next year

50 In My Experience
Rethinking Propofol
Is propofol during euthanasia doing more harm than good?

54 Home Team
The Resilient Leader
Resilience is the new measure of leadership competency

56 Podcast
Can Euthanasia Be Beautiful?
A conversation with Kathleen Cooney, DVM, CHPV, DACAW resident

the usual
9 From the Editor’s Desk
10 Inside AAHA
19 Notebook
62 Advertiser Index
63 AAHA Marketplace
64 Employee of the Month
HEARTWORM DISEASE IS ON THE RISE
The latest incidence map from the American Heartworm Society (AHS) shows an upward trend in the overall heartworm infection rates in the US. When you look more closely, you see the rates are trending upward in traditional hot spot areas, but more alarmingly, the rates are also rising in geographic locations with historically low heartworm rates.

IT ALL STARTS WITH YOUR RECOMMENDATION
When it comes to slowing this increase in heartworm disease, it all starts with recommending year-round heartworm disease prevention for all your canine patients.

Recent assessments show that approximately 68% of dogs seen by veterinarians in the US receive no heartworm disease prevention from that veterinary practice each year.¹³

Sponsored by Boehringer Ingelheim
This delicious, beef-flavored soft chew makes compliance easy

**DESIGNED WITH COMPLIANCE IN MIND**

When developing NexGard PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets), the Boehringer Ingelheim team worked to create a delicious, beef-flavored chew with a soft texture that is designed to be easy-to-give and provide an ideal experience for both your patients and their owners.

---

**IN A LABORATORY STUDY, DOGS PREFERRED**

**THE ONE YOU WANT FOR ONE-AND-DONE MONTHLY PROTECTION**

- Delicious, beef-flavored soft chew makes compliance easy and enjoyable
- The same proven dose of afoxolaner prescribed to millions of dogs
- Delivers an optimized dose of moxidectin that is safe and effective
- Safe for use in puppies as young as 8 weeks, weighing 4 pounds or more
- Backed by the exceptional SATISFACTION GUARANTEE from NexGard® Brand Products to give you peace of mind

---

*For dogs demonstrating a preference, they preferred NexGard PLUS chews over SIMPARICA TRIO.

**IMPORTANT SAFETY INFORMATION:** NexGard PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) is for use in dogs only. The most frequently reported adverse reactions reported in clinical trials were diarrhea, vomiting, lethargy, and itching. NexGard PLUS contains afoxolaner, a member of the isoxazoline class, which has been associated with neurologic adverse reactions including tremors, ataxia, and seizures in dogs with or without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of NexGard PLUS has not been evaluated in breeding, pregnant, or lactating dogs. Dogs should be tested for existing heartworm infection prior to starting a heartworm disease preventive. For more information, see full prescribing information or visit NexGardPLUSClinic.com.

**References:**

NexGard® is a registered trademark of Boehringer Ingelheim Animal Health France, used under license. All other trademarks are the property of their respective owner. ©2023 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-PET-0903-2023
NexGard® PLUS
(axoflolaner, moxidectin, and pyrantel chewable tablets)

For oral use in dogs only

Cautions: Refer to label to identify this drug to be used by or on the order of a licensed veterinarian.

Description:
NexGard® PLUS (axoflolaner, moxidectin, and pyrantel chewable tablets) is available in five sizes of beef flavored, soft chewable tablets for oral administration to dogs and puppies according to their weight. Each chewable tablet is formulated to provide minimum doses of 1.34 mg/lb (2.5 mg/kg) axoflolaner, 5.45 mcg/lb (12 mcg/kg) moxidectin, and 2.27 mg/lb (5.0 mg/kg) pyrantel (as pamoate salt).

Axoflolaner is a member of the isoxazoline family of compounds. Its chemical name is (E)-1,4,5,6-Tetrahydro-1-methyl-2-[2-(2-thienyl) vinyl] pyrimidine 4, 4' methylenebis-[3-hydroxy-2-naphthaldehyde (K12).

Contraindications:
Axoflolaner is contraindicated in dogs with prior history of axoflolaner reactions. Moxidectin is contraindicated in dogs with a history of neurologic adverse reactions including tremors, ataxia, and seizures. Severe hemorrhage has been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders.

Precautions:
Axoflolaner, one of the ingredients in NexGard® PLUS, is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Severe hemorrhage has been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders.

Treatment with fewer than six monthly doses after the last exposure to mosquitoes has not been evaluated and may not provide complete heartworm protection.

Prior to administration of NexGard® PLUS, dogs should be tested for existing heartworm infections prior to the start of the treatment. Infected dogs should be treated with an adulticide to remove adult heartworms. NexGard® PLUS is not effective against adult D. immitis.

The safe use of NexGard® PLUS in breeding, pregnant, or lactating dogs has not been evaluated.

Adverse Reactions:
In a field safety and effectiveness study, NexGard® PLUS was administered to dogs for the prevention of heartworm disease. The study included a total of 334 dogs (134 administered NexGard® PLUS and 338 administered active control) treated once monthly for 11 months. Over the 353 study period, all rates of potential adverse reactions were recorded. The most frequent reactions reported in the NexGard® PLUS group are presented in the following table.

Table 1. Dogs With Adverse Reactions

<table>
<thead>
<tr>
<th>Clinical Sign</th>
<th>NexGard® Number of Dogs (%)</th>
<th>Active Control Number of Dogs (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anorexia</td>
<td>9 (6.7)</td>
<td>7 (5.8)</td>
</tr>
<tr>
<td>Cough</td>
<td>6 (4.5)</td>
<td>11 (8.7)</td>
</tr>
<tr>
<td>Lethargy</td>
<td>3 (2.2)</td>
<td>8 (6.5)</td>
</tr>
<tr>
<td>Itching</td>
<td>2 (1.5)</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>Loss of appetite</td>
<td>4 (2.9)</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>1 (0.7)</td>
<td>4 (3.1)</td>
</tr>
</tbody>
</table>

One dog in the NexGard® PLUS group was reported to exhibit muscle tremors along with anorexia and depression for one day after the Day 28 treatment. The dog remained in the study and muscle tremors were not reported after any subsequent treatments.

Contact Information:
For a copy of the Safety Data Sheet (SDS) or to report suspected adverse drug events, contact Boehringer Ingelheim Animal Health USA Inc. at 1-888-677-4251 or www.nexgardforpets.com.

Clinical Pharmacology:
Mode of Action:
NexGard® PLUS (axoflolaner, moxidectin, and pyrantel chewable tablets) contains the three active pharmaceutical ingredients axoflolaner, moxidectin, and pyrantel (as pamoate salt).

Axoflolaner is a member of the isoxazoline family of compounds. It is a benzyl isoxazoline derivative that is similar in structure to the pyrrolidine and pyrazoline derivatives. It is selectively toxic to insects and acarines, but not to mammals. Axoflolaner acts by interfering with chloride channel-mediated neurotransmission in susceptible insects and acarines. This differential sensitivity between the insects and acarines' GABA receptors versus mammalian GABA receptors is inferred by the differential sensitivity of the insects and acarines' GABA receptors to insecticidal and acaricidal, but not to mammalian GABA receptors. The selective toxicity of axoflolaner against insects and arachnids and mammals may be attributed to the differences in the localization of GABA receptors in these different species. Axoflolaner kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and flea-borne diseases. NexGard® PLUS kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and flea-borne diseases.

Clinical Pharmacology:
NexGard® PLUS contains the three active pharmaceutical ingredients axoflolaner, moxidectin, and pyrantel (as pamoate salt).

Axoflolaner is a member of the isoxazoline family of compounds. It is a benzyl isoxazoline derivative that is similar in structure to the pyrrolidine and pyrazoline derivatives. It is selectively toxic to insects and acarines, but not to mammals. Axoflolaner acts by interfering with chloride channel-mediated neurotransmission in susceptible insects and acarines. This differential sensitivity between the insects and acarines' GABA receptors versus mammalian GABA receptors is inferred by the differential sensitivity of the insects and acarines' GABA receptors to insecticidal and acaricidal, but not to mammalian GABA receptors. The selective toxicity of axoflolaner against insects and arachnids and mammals may be attributed to the differences in the localization of GABA receptors in these different species. Axoflolaner kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and flea-borne diseases.

Clinical Pharmacology:
NexGard® PLUS contains the three active pharmaceutical ingredients axoflolaner, moxidectin, and pyrantel (as pamoate salt).

Axoflolaner is a member of the isoxazoline family of compounds. It is a benzyl isoxazoline derivative that is similar in structure to the pyrrolidine and pyrazoline derivatives. It is selectively toxic to insects and acarines, but not to mammals. Axoflolaner acts by interfering with chloride channel-mediated neurotransmission in susceptible insects and acarines. This differential sensitivity between the insects and acarines' GABA receptors versus mammalian GABA receptors is inferred by the differential sensitivity of the insects and acarines' GABA receptors to insecticidal and acaricidal, but not to mammalian GABA receptors. The selective toxicity of axoflolaner against insects and arachnids and mammals may be attributed to the differences in the localization of GABA receptors in these different species. Axoflolaner kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and flea-borne diseases.

Clinical Pharmacology:
NexGard® PLUS contains the three active pharmaceutical ingredients axoflolaner, moxidectin, and pyrantel (as pamoate salt).

Axoflolaner is a member of the isoxazoline family of compounds. It is a benzyl isoxazoline derivative that is similar in structure to the pyrrolidine and pyrazoline derivatives. It is selectively toxic to insects and acarines, but not to mammals. Axoflolaner acts by interfering with chloride channel-mediated neurotransmission in susceptible insects and acarines. This differential sensitivity between the insects and acarines' GABA receptors versus mammalian GABA receptors is inferred by the differential sensitivity of the insects and acarines' GABA receptors to insecticidal and acaricidal, but not to mammalian GABA receptors. The selective toxicity of axoflolaner against insects and arachnids and mammals may be attributed to the differences in the localization of GABA receptors in these different species. Axoflolaner kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and flea-borne diseases.
from the editor’s desk

HELLO READERS! I almost called this issue the Inventory Issue, but I didn’t want to scare anyone away. Inventory might not be the most exciting topic you have ever thought of, but don’t tell that to Nicole Clausen, CSSGB, CCFP. The self-proclaimed inventory nerd has five great tips for you to get your inventory management under control for the new year.

Speaking of inventory, we also have an article from Lowell Ackerman, DVM, DACVD (Emeritus), MBA, MPA, CVA, MRCVS, on what you should stock in your pharmacy for 2024. Ackerman acknowledges that most practitioners are not super excited about thinking about inventory—but it is important for keeping track of profitability, and we all like profits!

Almost as titillating as inventory is practice finance—but once again, it comes down to the question of “are you making money?” Karen E. Felsted, CPA, MS, DVM, CVPM, CVA, makes it easy to perform a profit checkup with her expert advice.

Of course, you don’t want to miss reading the executive summary of AAHA’s latest guidelines, the 2023 AAHA Management of Allergic Skin Diseases in Dogs and Cats Guidelines. This is one of our most anticipated guidelines, and for good reason. An amazing task force has brought together the best brains in the business when it comes to itchy pets. Of course, you can read and download the entire guidelines from either jaaha.org or aaha.org/allergic-diseases.

Our podcast article this month is a conversation with Kathleen Cooney, DVM, CHPV, DACAW resident, founder of the Companion Animal Euthanasia Training Academy (CAETA). Cooney tries to answer the question: can euthanasia be a beautiful thing? It is not always, but it definitely can be.

THE TRENDS EMPLOYEE OF THE MONTH CONTEST—EVERYBODY WINS
Do me a favor. Right now, go to aaha.org/EOTM and nominate one of your coworkers for the employee of the month contest. Then, have them nominate you! When you enter our monthly drawing, the winner will win a $400 gift card, and the person who nominated them will receive a $100 gift card from Amazon! This is your chance to shine the spotlight on one of your best employees, and win some loot for doing so. If you don’t win, don’t worry, you can enter again the next month! Enter today at aaha.org/EOTM.

COMING NEXT MONTH
We have a great surprise for you in January. I won’t give it away, but it is something that has not been done in more than 10 years here at Trends. Can you guess? You won’t be disappointed! As for the article topics, we are going to get into tech utilization, telehealth, and staff retention and also take a dive into the wild world of artificial intelligence.

As always, let me know what you think at trends@aaha.org.

—Ben Williams, Editor
View from the Board

Numbers Don’t Lie

I can’t speak for everyone, but I can say that when I entered veterinary school, I did not do so with the intention of hoping to someday worry about inventory management and watching key performance indicators (KPIs). I entered veterinary medicine because it was exciting, and I loved the challenge of helping those who cannot speak for themselves. I loved the problem-solving component mixed with science. At no point did I fantasize about watching KPIs, much less worrying about how those KPIs would affect my staff, myself, and occasionally my patients and clients. Even when I became a partner in a practice, I didn’t fully understand the importance of watching them. It wasn’t until I became a sole owner that I realized just how important KPIs are to the health of my practice. Fast forward to now, and I am watching my KPIs regularly. I am making strategic practice decisions based on trends in my KPIs and have a much healthier practice because of it.

I learned pretty quickly in practice that while going with a gut feeling is important, it is not a good bellwether from which to make decisions. Generally, numbers don’t lie. They can be skewed, even ignored, but they don’t lie. When I started watching KPIs such as payroll, cost of goods/inventory, taxes, electricity/water, and so on, it became apparent that when costs of things increased, that directly affected profitability and my ability to reinvest in the practice. I found that the easiest way for me to manage that was by watching my inventory and cost of goods like a hawk. Holding myself accountable to a budget set based on my KPIs had the most direct effect on my ability to pay my staff. When the hospital is more profitable, there is more money as a percentage of gross for payroll. This makes for happier staff, and I can feel better knowing that I am supporting them at a higher level financially than I was able to previously.

The things I found that helped control my inventory are not new ideas. Practice consultants have been talking about them for years. I did not create these ideas, I just started listening to them and implemented the ones that seemed to make the most sense. The biggest help was not carrying multiple versions of items that did the same thing. This includes things like heartworm prevention. In my area this is easily the largest percentage of inventory, and limiting the options that I carry in house did a great job of helping the bottom line. The same goes for ear medication and anti-inflammatories. Yes, we have an online store for the one-offs, but that is still pretty minimal. With in-house pharmacies shrinking due to online options, it is important to not have a lot of money sitting on the shelf collecting dust when it can be put to use in other ways, such as updated equipment, new areas of revenue, or staff payroll.

My recommendation is to not rely on any gut feeling. Every hospital should have someone who geeks out on the numbers to help guide the ship and make strategic decisions that are in the best interest of the business. Numbers don’t lie, but they also don’t tell you anything if you don’t look at them.

Scott Driever, DVM, is president-elect of the AAHA board. Driever is a Houston native who received his DVM degree from Texas A&M University in 2000. Upon graduation, he moved back to Houston and began his veterinary career at Animal Hospital Highway 6 in Sugar Land, Texas, where he became a partner in 2005. In 2015, he purchased the rest of the practice and became the sole owner. His wife, Susan, is the office manager at the practice.
This month in AAHA’s Publicity Toolbox . . .

Here are the downloadable social media images available for AAHA-accredited members at aaha.org/publicity this month:

If you’re cold, they’re cold.
Season’s Greetings
National Cat Lovers Month
Happy New Year’s Eve
December 31

What Does Your Fire Evacuation Plan Look Like?

We have been revamping our Safety and Health SOP, and evacuation plans are top of mind. We have a fire evacuation plan and a group meeting place; however, we would love to hear from others when it comes to their protocol. Thanks in advance!

A: AVMA also has a Safety Standards regarding a written disaster and emergency management plan. Check them out here: avma.org/resources-tools/animal-health-and-welfare/disaster-preparedness.

A: Call your local fire department and ask them to help set up a plan. They were great!

Community

Help a peer by adding your thoughts to the conversation at community.aaha.org. Questions about your membership? Email community@aaha.org.
New Device Gives Voice to Animals’ Pain

by Emily Singler, VMD

How often do you find yourself trying to convince a client that their pet is in pain, even though they aren’t crying? How about those times when you are wondering if your patient’s behavioral changes may be pain-related? The practice of veterinary medicine is undoubtedly more challenging because our patients cannot verbalize what they are feeling.

We are, of course, experts at reading animal body language and gleaning as much information as we can from it. But there are still times when it is hard to know how much pain our patients are experiencing. A new device called PainTrace is changing all that by “giving a voice to pain.”

To learn more, I caught up virtually with three representatives of BioTraceIT, the manufacturer of PainTrace. Deb Dullen, president and CEO; Ralph Harvey, DVM, MS, DACVAA, chair of the veterinary advisory board; and Katie Hickey, global clinical program director, joined me on a call from the National Institutes of Health (NIH) Pain in Animals Workshop in Bethesda, Maryland, to share more.

What Is PainTrace?

As Harvey, a veterinary anesthesiologist, eloquently described it, “the language of pain is electrical activity.” PainTrace is a small device about the size of a deck of cards that is attached by a cable to two small metal sensors created to measure skin-based electrical activity that is indicative of pain within the body.

This noninvasive device boasts the ability to measure both acute and chronic pain, to document trends in pain levels over time, and to help localize pain in the body.

“It takes on the individualized experience of pain,” Dullen said, which includes not only the physical sensation but also the psychological and social aspects of pain.

How Does It Work?

PainTrace is designed to be used in the veterinary clinic during a physical examination, while the patient is moving, during a surgical or dental procedure, or during recovery from a procedure. The sensors are placed and acquire a systemic signal comprising the whole body, regardless of the suspected pain localization.

Once the sensors are applied to the skin with an adhesive, the device communicates wirelessly with an iPad equipped with PainTrace software, allowing for real-time electrical readings that determine a patient’s “pain score,” which is a cumulative measurement of pain throughout the patient’s body.

On the iPad, users will see a graph with a line tracing of the pain score of the patient and how it changes (if applicable) as the patient moves or when certain parts of the body are touched or manipulated. This helps veterinary professionals to localize the pain and determine its severity.
According to Harvey, PainTrace can detect pain that was otherwise not detectable on physical examination, even by experienced practitioners. Pet owners can also witness the results in real time and have a more tangible indicator of their pet’s pain.

How Have the Results Been Validated?
Much of the initial research and development was conducted in humans, who thankfully can verbalize their pain to corroborate the electrical readings. In patients, functional magnetic resonance imaging has been used to measure changes in the brain that are known to be consistent with pain responses. These findings were correlated with pain score readings from PainTrace.

Harvey and Hickey performed a live demonstration for me on the call. Harvey, who has been diagnosed with arthritis in one of his wrists, applied the sensors to his skin. Hickey showed me the pain score tracing on an iPad while she flexed one of Harvey’s wrists and then the other. There was a clear spike in the pain score reading when Harvey’s painful wrist was flexed, but no spike when his other wrist was flexed.

Case Summary: A Paralyzed Dog Gets a Second Chance
Harvey also shared a case summary to illustrate the value of PainTrace. A dog with a spinal injury had become paralyzed. The dog was treated with physical therapy for weeks and did not appear to be improving. The dog owners were strongly considering euthanasia because of poor quality of life.

The treating veterinarian had a PainTrace device and decided to use it to look for any evidence of spinal cord activity. With the device connected, the veterinarian performed a toe pinch and plantar pinch and measured an electrical response. This was enough to convince the owners to hold off on euthanasia and wait a little longer. The dog is now walking, albeit not perfectly.

Future Impacts on Patient Care
Dullen suggests that the implications of more widespread use of PainTrace are significant. “Veterinarians report that when pet owners see pain live, they are more motivated to make a decision with the vet to treat their pet’s pain,” she said, meaning more animals will get the relief they need.

This technology also presents a new diagnostic option for animals who cannot safely be handled without chemical restraint, since PainTrace can still obtain accurate readings in sedated or anesthetized patients.

Future Impacts on Team Wellbeing
The device may also make a positive impact on the mental wellbeing of veterinary personnel. Dullen said that based on published research, one of the biggest contributors to veterinary staff wellbeing is client satisfaction at the time of the visit. When pet owners partner with their veterinary team to provide the care that their pet needs, veterinary personnel can experience greater job satisfaction and improved wellbeing.

Clinical Trials Are Ongoing
The BioTraceIT team has big plans for PainTrace. Clinical trials are ongoing to gain FDA approval for human clinical use. The team also envisions a future where the device is already on hand in pet owners’ homes, for use with both humans and animals. In this scenario, the veterinary team could instruct the pet owner to obtain their pet’s pain score at home to either triage or monitor their pet’s condition.

PainTrace was created to “speak for animals who have no voice,” Harvey said. Hopefully, this technology can also help strengthen our bonds with our patients and our clients.

Further reading

Observational Study Monitoring Pain in 25 Dogs

Want more vet med news?
Subscribe at aaha.org/newstat

PainTrace Resources
paintrace.com/resources
New Study Explores Vaccine Hesitancy in Dog Owners
by Emily Singler, VMD

Many of us have had experiences with pet owners who refuse vaccines for their pets. These owners will offer a variety of reasons for their resistance, or sometimes no reason at all. Up until now, we have only had anecdotal evidence of this trend. Now, for the first time, researchers have started to quantify vaccine hesitancy in dog owners.

Matt Motta, PhD, assistant professor of health law, policy, and management at Boston University School of Public Health; Gabriella Motta, VMD, associate veterinarian at Glenolden Animal Hospital; and Dominik Stecula, PhD, assistant professor of political science at Colorado State University, recently conducted a study on canine vaccine hesitancy (CVH) and some of its causes and effects.
The Mottas, brother and sister, spoke with me and shared their motivation for conducting this research. They report that all three coauthors have been “aware for years” that some dog owners don’t want to vaccinate their dogs.

**From a Campfire to Cross-Disciplinary Research**
Matt Motta, a researcher who has studied vaccine hesitancy in humans, and Gabriella Motta, a small animal veterinarian working in the trenches, recall sitting around a family campfire, trading “horror” stories from work. The subject of vaccine hesitancy came up.

Seeing that there were a lot of anecdotal similarities between their experiences with humans and animals, they kept talking about it. They continued that conversation “for a while,” Matt Motta said, comparing human vaccine hesitancy, particularly to the COVID-19 vaccine, to pet owners who refused to vaccinate their dogs.

But unlike in human medicine, the authors noted that no one had made an effort to quantify vaccine hesitancy in animal owners or determine the effects of this behavior on public health and health policy. So, they set out to do just that.

**Factors of Vaccine Hesitancy**
According to Matt Motta, their findings suggest that the same factors (political party, level of education, promotion of vaccine misinformation, and others) that make people less likely to have a positive opinion of vaccines for themselves negatively affect their opinions on vaccines for their dogs.

This has been termed the “vaccine spillover effect,” whereby views toward one vaccine affect views toward other unrelated vaccines. Matt Motta wrote in another article that negative attitudes toward the COVID-19 vaccine may be spilling over into attitudes toward mandatory vaccination of children for other diseases, for example.

**The Rabies Example**
The researchers documented that, among the dog owners surveyed, 37% found canine vaccines to be unsafe; 22% found them to be ineffective; and 30% found them to be unnecessary. Fifty-three percent of dog owners agreed with at least one of these positions.

In terms of the canine rabies vaccine specifically, 84% of dog-owning respondents indicated that they were sure that their dog was up to date with their rabies vaccine. Forty-eight percent of respondents opposed mandatory rabies vaccination for pets, believing that the decision to vaccinate should be left to the pet owner.

The sequelae of vaccine hesitancy in pet owners can be detrimental to both human and animal health, particularly in the case of rabies vaccination. Whereas transmission of rabies from dogs to humans can be largely prevented by vaccinating at least 70% of dogs in high-risk areas, the study authors report, areas where this 70% canine vaccination threshold is not met typically can see thousands of human deaths from rabies each year.

Opposition to rabies vaccine laws may contribute to relaxation and/or eradication of such laws in some municipalities, increasing the public health risk in those areas.

**Vaccine Hesitancy and Veterinary Wellbeing**
CVH also likely negatively affects the mental wellbeing, stress, and burnout levels of veterinary professionals, the researchers add. When pet owners disregard our expert advice to vaccinate their pets, the veterinary professional–client relationship can be damaged.

Conflict can also arise when unvaccinated animals are denied services such as boarding, surgeries, or nail trims to protect other animals, especially when veterinary staff and owners don’t understand or agree with the decision. Veterinary professionals who do handle unvaccinated animals can experience increased stress as they worry about exposure to themselves, their coworkers, and their other patients.

The Mottas agree that their study is just the beginning. Future work will measure feline vaccine hesitancy, collect more qualitative information about why pet owners are hesitant to vaccinate their pets, and try to document correlations between infectious disease trends and vaccine hesitancy in pet owners.

They also plan to study any proposed changes to rabies vaccine laws in the past 40 years to determine how often changes have been made, why the changes were proposed, and what the effects of those changes have been.
Is Vaccine Hesitancy a Messaging Problem?
When asked if vaccine hesitancy in pet owners shows a messaging problem in veterinary clinical practice, the Mottas each relayed their own experiences. Matt Motta responded that, in his research with human vaccine hesitancy, “one of the best predictors of how people feel about medicine is how people feel about science and experts.” These feelings can be affected by a number of factors, including political party affiliation and religion.

Gabriella Motta added that it is important at the clinical level to try to understand why any individual client might not want to vaccinate. While this won’t always be the case, there may be some opportunities to refute any misinformation and help increase client trust so that they reconsider vaccination.

She also points out the importance of discussing vaccines and preventive care with clients who only tend to seek veterinary care when their pets are sick. These clients may not always be aware of what their pets are missing from vaccinations, and they may not understand the value of preventive care in their pets’ lives.

As these studies continue, the Mottas hope that others will join them in looking for solutions to protect animal and human health, while fostering trust between pet owners and their veterinary teams. *

Further reading
Sick as a Dog? The Prevalence, Politicization, and Health Policy Consequences of Canine Vaccine Hesitancy (CVH)
offi/0reprints/socarxiv/qmkbv
Is partisan conflict over COVID-19 vaccination eroding support for childhood vaccine mandates?
nature.com/articles/s41541-023-00611-3

Emily Singlet, VMD, is a 2001 graduate of Penn State University and a 2005 graduate of University of Pennsylvania School of Veterinary Medicine. Her career in veterinary medicine has included experience in shelter medicine, in private practice, and as a relief veterinarian. She currently works as a veterinary writer, consultant, and mentor and enjoys writing for both pet owners and veterinary professionals. Her writing interests include public health, preventive medicine, the human-animal bond, and life as a working mom. She is the author of Pregnancy and Postpartum Considerations for the Veterinary Team, which was published by CRC Press in November 2023 and is available to order now at www.emilysingletvmd.com.

As these studies continue, the Mottas hope that others will join them in looking for solutions to protect animal and human health, while fostering trust between pet owners and their veterinary teams.

*CLARO® (florfenicol, terbinafine, mometasone furoate) Otic Solution for use in dogs only
Do Not Use in Cats.

Wear eye protection when administering CLARO®. (See Human Warnings, PRECAUTIONS, POST-APPROVAL EXPERIENCE.)
WIN THE FIGHT AGAINST OTITIS EXTERNA

Save your clients from the stress of OE treatment

Proven Efficacy
Effective against your most common cases of OE

One-Dose Convenience
Provides a full course of therapy

Administered by You
Eliminates concerns of missed or incorrectly applied doses

Choose Claro®, the trusted market leader in OE treatment.²

Claro® is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. PRECAUTIONS: For use in dogs only. Do not use in cats. (See POST-APPROVAL EXPERIENCE.) CLARO® has been associated with rupture of the tympanic membrane. Reevaluate the dog if hearing loss or signs of vestibular dysfunction are observed during treatment. Signs of internal ear disease such as head tilt, vestibular signs, ataxia, nystagmus, facial paralysis, and keratoconjunctivitis sicca have been reported (see POST-APPROVAL EXPERIENCE) with the use of CLARO®. Wear eye protection when administering CLARO®. (See Human Warnings, PRECAUTIONS, POST-APPROVAL EXPERIENCE.)


©2022 Elanco or its affiliates. Claro, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-22-0914
Educating pet owners about the symptoms, treatment, and management of pet diabetes, so they can seek appropriate treatment for their dog or cat, is the goal of Pet Diabetes Month.

Early detection of pet diabetes is critical to proper management, and actively promoting diabetes awareness shows leadership from your clinic.

It is estimated that 1 in 300 adult dogs and 1 in 230 cats in the U.S. have diabetes.1,2

Use your social media channels, such as your clinic’s Facebook page, to create interest in your program and spread awareness with #PetDiabetesMonth!

Learn more at usa.petdiabetesmonth.com.


Important Safety Information: VETSULIN® and VETPEN® are for use in animals only. Dogs and cats known to have an allergy to pork or pork products should not be treated with VETSULIN®. VETSULIN® is contraindicated during periods of hypoglycemia. Animals with severe ketoacidosis, anorexia, lethargy, and/or vomiting should be stabilized with short-acting insulin and appropriate supportive therapy before use. As with all insulin products, careful patient monitoring for hypoglycemia and hyperglycemia is essential. Overdosage can result in profound hypoglycemia and death. Progestogen and glucocorticoid use should be avoided. The safety and effectiveness of VETSULIN® in puppies, kittens, breeding, pregnant, and lactating dogs and cats has not been evaluated. Keep out of reach of children. Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for at least 15 minutes. Accidental injection may cause clinical hypoglycemia. In case of accidental injection, seek medical attention immediately. Exposure to the product may induce a local or systemic allergic reaction in sensitized individuals. For complete safety information, refer to the product label.

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. US-CAN-230800004
Hemodialysis Helps Dog Defy Odds of 10% Survival Rate After Antifreeze Poisoning

The UC Davis School of Veterinary Medicine News recently reported the successful treatment of a dog who had consumed antifreeze. In the fall of 2022, Mija, a rescued two-year-old Australian cattle dog mix, explored the garage of Ana Alexander, her rescuer, and chewed into a bottle of antifreeze. Alexander rushed the vomiting Mija to a local veterinary emergency room, where the prognosis was bleak—Mija had only about a 10% chance of survival. Her kidneys were failing due to antifreeze (ethylene glycol) poisoning.

When Mija arrived at the UC Davis veterinary hospital, the only facility in Northern California able to treat her extensive organ injuries, doctors concluded that Mija needed hemodialysis. But even with many rounds of dialysis, the chances of Mija’s recovery were low.

Alexander agreed to dialysis. She learned how to tube feed Mija and to provide extensive home care. Over the next four weeks, Mija received eight dialysis treatments. She progressed to eating on her own and to weekly and then monthly appointments.

A year later, Mija’s condition is no longer life-threatening. Alexander reports she is full of energy and is doing exceptionally well.

Nationwide’s 15th Annual Hambone Award Winner

Giles, a New York City cat who was inadvertently smooshed under a sofa bed, has captured the 15th annual Hambone Award for the most unusual pet insurance claim of the year. Nationwide presents the award to bring awareness to the unique and surprising things that can happen to pets—and how pet insurance plays a role in helping them.

Giles, adopted from a cat rescue, lives happily in a New York City apartment with owners Reid and Kaitlyn, who reported he has a newfound aversion to hinged objects.

The runners-up were Jax, a pug from Las Vegas who got heat stroke while cozied up in a comforter following surgery, and Sunny, a determined Labrador retriever from Anaheim who shimmied his crate five feet across the room to ingest three phone charger cords. The families of Jax and Sunny each receive a gift card and the opportunity for a charity donation to be made in each pet’s honor.

All nominated pets have recovered and received reimbursements for eligible veterinary expenses from Nationwide pet insurance.
FDA Conditionally Approves Canine Seizure Medication Fidoquel-CA1

The US Food and Drug Administration has granted Genus Lifesciences Inc. conditional approval of Fidoquel-CA1 (phenobarbital tablets) for the control of seizures associated with idiopathic epilepsy in dogs. Idiopathic epilepsy is a type of seizure disorder without a known cause and is a serious or life-threatening condition that affects approximately 5% of dogs.

Unapproved phenobarbital tablets from the human drug marketplace have historically been used in veterinary medicine to help control seizures in dogs. Fidoquel-CA1 are the only phenobarbital tablets that have received the agency’s conditional approval for safety, quality manufacturing, and reasonable expectation of effectiveness.

Initial conditional approval is valid for one year with the potential for four annual renewals. During this time, the animal drug sponsor must demonstrate that it is actively working toward collecting the remaining effectiveness data needed to achieve full approval.

Researchers Exploring Data and AI Tools for Animal Health Diagnosis and Treatment

Stefan Keller, DVM, PhD, DECVP, an assistant professor and pathologist in the School of Veterinary Medicine at UC Davis, is exploring ways to use AI in three projects with colleagues from the university’s Artificial Intelligence in Veterinary Medicine Interest Group. The projects are:

1. Identifying Patterns with AI Tools
   Keller and team are developing a machine learning algorithm (called a “classifier”) that uses historical patient data to reduce errors in the interpretation of blood tests and to avoid inaccurate diagnoses. The project is funded by the UC Davis Venture Catalyst Science Translation and Innovative Research (STAIRTM) grant program.

   “We have thousands of . . . blood test data from over the past decades; if we take all that and run it through our algorithm, we can predict what disease the pets might have and what the prognosis might be,” Keller said.

2. Standardizing the Assessment of Inflammation
   In Keller’s second project, the team is investigating the assessment of inflammation in inflammatory bowel disease in aged cats. Keller sees an opportunity to standardize the assessment of inflammation and share it with clinicians by digitizing the data and running AI algorithms on it.

3. Automating Patient Diagnosis in Real Time
   Currently, scientists manually pull the data from a patient database onto a computer, run the classifier on that data locally, and then provide the information back to the clinician. Keller’s team is working on shortening the process by hosting the classifiers on a shared platform and feeding the patient data directly into it so the patterns can be detected in real time.

While the initial application is for dogs, the team sees an opportunity to adapt the tool for cats and horses.
CareVet, Blendvet, and Hill’s Launch DEIB Initiative
CareVet, a leading network of veterinary hospitals, has announced a strategic partnership with Blendvet and Hill’s Pet Nutrition to integrate diversity, equity, inclusion, and belonging (DEIB) content into its companywide CareVet Learning Institute. Hill’s Pet Nutrition sponsored this integration as part of its ongoing commitment to creating a significant and lasting impact on the veterinary medical community.

The partnership fosters inclusivity and belonging in workplace environments for veterinary teams, clientele, and the community. On-demand modules developed by Blendvet and hosted on CareVet Learning Institute are available to veterinary professionals within CareVet’s network.

The modules introduce veterinary professionals to critical DEIB issues prevalent in the industry; promote creative thinking; and ignite positive change within the workplace. The Blendvet modules, the nation’s first and only veterinary-curated DEIB training curriculum, empower veterinary hospitals to cultivate a more inclusive workplace by offering both individual certification and hospital certification.

Immunotherapy Drugs Bring Years of Life to Dog
The life expectancy of most dogs who develop metastatic osteosarcoma is only 8 to 10 weeks. Jelly Bean, a Labrador retriever mix, has survived for nearly three years thanks to a clinical trial at Tufts University’s Cummings School of Veterinary Medicine. Her progress may hold clues for treating osteosarcoma in dogs and, one day, people.

“The ability of the novel oral immunotherapy combination to induce a complete remission of Jelly Bean’s cancer laid the groundwork for a prospective study of this therapy in dogs with osteosarcoma, given prior to the development of resistance,” said Cheryl London, DVM, PhD, DACVIM, associate dean of research and graduate education and director of the Clinical Research Shared Resource. “We found that the immunotherapy regimen was equivalent to standard chemotherapy. Ultimately, our goal is to combine the immunotherapy regimen with chemotherapy to further improve outcomes in both dogs and people.”
AVMA Champions Efforts to Address Rural Veterinary Shortages

The Rural Veterinary Workforce Act, formerly known as the Veterinary Medicine Loan Repayment Program (VMLRP) Enhancement Act, has been reintroduced in both the House and Senate after months of collaborative work by the American Veterinary Medical Association (AVMA), other stakeholder organizations, and congressional offices.

Championed by the AVMA, the bipartisan legislation would expand the reach of the VMLRP—a program that helps increase access to food animal veterinary services in rural areas by assisting with the significant obstacle of educational debt. The Rural Veterinary Workforce Act would end the federal taxation on VMLRP awards, which would enable more veterinarians to participate in a program that offers up to $75,000 over three years for student loan repayment in exchange for service in U.S. Department of Agriculture (USDA)—designated shortage areas. This would make the tax treatment of the awards the same as for the analogous program for physicians.

In 2023, the USDA declared 237 rural veterinary shortage areas in 47 states, which is more than any year to date. Since 2010, USDA awarded 795 VMLRP awards to veterinarians; meanwhile, 2,061 applications have been received to participate in the program since its inception.

“Increasing veterinary services in high-priority rural areas through the Rural Veterinary Workforce Act would help keep the nation’s livestock healthy and our food supply safe and secure, and protect public health,” said Rena Carlson, DVM, AVMA president.

Destination Pet Removes Noncompete Clauses in Employment Contracts for Veterinary Professionals

Destination Pet LLC, a premier provider of veterinary care and pet services, has eliminated the noncompete clause from employment contracts for veterinarians. All currently employed Destination Pet veterinarians have been released from any noncompetition agreements they had with Destination Pet or its subsidiaries.

Destination Pet belongs to a growing number of employers who have chosen to eliminate noncompete clauses in their employment agreements with veterinary professionals.

While Destination Pet is waiving the enforcement of noncompetition provisions, nonsolicitation provisions will remain in effect. Noncompete provisions will still apply as part of the sale of a business for prior practice owners.
Texas A&M Veterinarians Developing Frailty Instrument to Improve Canine Geriatric Care

Measuring frailty is a vital aspect of human geriatric care. Frailty considers physical, mental, and emotional changes associated with aging and is a better indicator of the body's condition and overall health than age. Now, the Dog Aging Project, a collaborative program led by the Texas A&M School of Veterinary Medicine & Biomedical Sciences (VMBS) and the University of Washington School of Medicine, is creating a frailty instrument that can be used to make health decisions and personalize geriatric veterinary care for dogs.

The plan for developing this instrument, using a variety of simple tests and questionnaires that can be performed by dog owners and veterinarians, was recently published in *Frontiers in Veterinary Science*.

Once the Project team members have narrowed down the questions that most effectively determine a dog’s frailty, they will develop a numerical frailty scale that general veterinary practitioners can use. After that, they plan to expand the scale into a full Frailty Instrument for Dogs to increase its usefulness in real-life situations.

Especially in an emergency room setting, knowing a dog’s frailty score will help manage owner expectations and ensure that the medical decisions being made accurately consider the dog’s prognosis and quality of life.

FDA Releases Plan for Supporting Antimicrobial Stewardship

Antimicrobials are crucial for treating infections, but nonjudicious use of these therapeutics can lead to the evolution of resistant bacteria. The FDA’s Center for Veterinary Medicine (CVM) has long been committed to antimicrobial stewardship in animals to help preserve the effectiveness of antimicrobial drugs and slow the development of antimicrobial resistance.


The five-year plans are intended to provide stakeholders with a transparent roadmap of the actions that correspond to FDA’s three main veterinary stewardship goals:

1. Align antimicrobial drug product use with the principles of antimicrobial stewardship.
2. Foster stewardship of antimicrobials in veterinary settings.
3. Enhance monitoring of antimicrobial resistance and antimicrobial drug use in animals.

For continuity, the new five-year plan begins in Phase 3 and is organized under the same overarching goals and objectives.

Stakeholders and the public can see what FDA has accomplished thus far and follow progress on the FDA website.

Read the 2022 AAFP/AAHA Antimicrobial Stewardship Guidelines, available at aaha.org/antimicrobials
SGLT2-inhibitor velagliflozin simplifies treating feline diabetes

Sponsored by Boehringer Ingelheim

Diabetes mellitus (DM) is one of the most common endocrinopathies in cats. While many cats experience good quality of life with dietary management and twice-daily insulin therapy, many owners may struggle with schedule disruption, needle phobia, and worry over potential hypoglycemia. The unfortunate result is euthanasia for up to 30% of feline diabetics at or within 1 year of diagnosis.1,2

In the last year, the FDA approved 2 oral sodium-glucose cotransporter-2 (SGLT2) inhibitors for use in newly diagnosed diabetic cats. BEXACAT™ (bexagliflozin tablets), which comes in oral tablet form, and SENVELGO® (velagliflozin oral solution), a liquid oral solution that’s administered directly in the cat’s mouth or on a small amount of wet food. For owners, a needle-free, once-daily treatment option could greatly simplify managing the disease.

SGLT2 inhibitors such as empagliflozin and dapagliflozin have treated type 2 diabetes mellitus (T2DM) in humans for over 10 years. They work by decreasing renal reabsorption of glucose, resulting in glucose loss through the urine and subsequent decreased blood glucose concentration (BG). SGLT2 inhibitors also have cardio- and renoprotective effects in people.

For felines, velagliflozin demonstrated its clinical efficacy in a pivotal field trial.3 Two hundred fifty-two diabetic cats were enrolled—214 were newly diagnosed (ND), and 38 were previously treated with insulin (IT). One hundred fifty-eight cats (70%) completed the extended use period of the study; 26 cats were removed for reasons unrelated to velagliflozin treatment, and 68 cats were removed for poor clinical response (16 cats) or adverse events (52 cats). By day 180, 81% of the remaining cats had BG or fructosamine concentration within reference range: 89% and 88% had improvement of polyuria and polydipsia, respectively. No cats developed clinical hypoglycemia.

The most common side effect in the trial was diarrhea, which occurred in 50% of the cats. In most cases, diarrhea was mild and self-limiting. Only 2 cats were removed from the study because of diarrhea.

The most severe side effect was diabetic ketoacidosis (DKA), which occurred in 18 cats. During the first 2 weeks of treatment, 14/18 cats developed DKA, suggesting the need for close monitoring during this period. A significantly higher percentage of IT cats (7/38—18%) developed DKA than ND cats (11/214—5%). This compares favorably to a study in which 6% of diabetic cats treated with insulin presented with DKA.4

Although IT cats were included in the velagliflozin study, SENVELGO oral solution is only approved by the FDA for use in ND cats.

The ideal velagliflozin patient is an otherwise healthy, uncomplicated diabetic cat that is eating and drinking, hydrated, and has no evidence of decreased appetite, vomiting, or diarrhea. Prior to treatment with velagliflozin, a minimum data base including complete blood count, serum biochemistry, IT4, urinalysis, fructosamine, and assessment of ketones is indicated for baseline evaluation and to rule out concurrent disease and ketosis.

Monitoring the success of velagliflozin treatment focuses on assessing physical exam (PE) and clinical signs, and evaluating parameters associated with glucose control and DKA. It’s also crucial for owners to look for indicators of ketosis and DKA—decreased appetite, lethargy, and vomiting. While the trial reported no clinical hypoglycemia, you should monitor cats for signs of hypoglycemia, including lethargy and neurologic signs.

When beginning velagliflozin therapy, perform rechecks at days 2–3, 7, and 14 to proactively identify DKA. PE parameters suggestive of developing DKA include dehydration and weight loss. Although many cats lose weight within the first 2–3 days of therapy without developing DKA, significant weight loss (>8%) suggests the need for closer monitoring over the next few days. Using a handheld ketone meter that measures beta hydroxybutyrate (BHB) is ideal, but urine dipsticks are also effective.

Most cats will improve clinical signs, glucose, and fructosamine within 30 days. If no improvement is seen at 30 days or ketosis occurs at any time (positive urine dipstick or >2.4 mmol/L on a handheld meter), discontinue velagliflozin and start the cat on insulin therapy.

In summary, velagliflozin is a promising once-daily liquid oral solution for treating feline DM. Most cats experience improvement of clinical signs and glycemic parameters within 30 days. Diarrhea is common, but usually mild and self-limiting. Euglycemic diabetic ketoacidosis (eDKA) is the most severe side effect; although uncommon (5% of ND), proactive monitoring by the owner and veterinary team is crucial for prevention and early detection.

Patty Lathan, VMD, MS, DACVIM (SAIM)
Professor, Small Animal Internal Medicine
Louisiana State University
Baton Rouge, Louisiana

3. SENVELGO® (velagliflozin oral solution) prescribing information.

NEW!
Although IT cats were included in the velagliflozin study, SENVELGO oral solution is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.

**IMPORTANT SAFETY INFORMATION:**

SENVELGO® (velagliflozin oral solution) is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin. Before using this product, it is important to read the entire product insert, including the boxed warning.

Cats treated with SENVELGO may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. Development of these conditions should be treated promptly, including insulin administration and discontinuation of SENVELGO.

Do not use SENVELGO in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. The use of SENVELGO in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of SENVELGO, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death.

Sudden onset of hyporexia/anorexia, lethargy, dehydration, or weight loss in cats receiving SENVELGO should prompt immediate discontinuation of SENVELGO and assessment for diabetic ketoacidosis, regardless of blood glucose level. SENVELGO should not be initiated in cats with ketonuria, ketonemia, pancreatitis, anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis.

Keep SENVELGO in a secure location out of reach of children, dogs, cats, and other animals to avoid accidental ingestion or overdose. For more information, please refer to the enclosed package insert or visit SENVELGOClinic.com.

**Scan for more details!**

**NEW!**

**SENVLEGO®** (velagliflozin oral solution)

**JUST WHAT CATS ORDERED**

*A convenient, once-daily liquid oral solution for feline diabetes*

- Delivers sustained glycemic control starting as soon as 1 week for most cats\(^1,\!\!^2\)
- Precise dosing tailored to the cat’s weight
- Minimal risk of clinical hypoglycemic events\(^3\)
- Well accepted by most cats\(^3\)

*Based on average cat weight of 11 lbs
1. Data on file at Boehringer Ingelheim.
3. SENVELGO® (velagliflozin oral solution) prescribing information.

**SENVELGO® and the SENVELGO Logo® are registered trademarks of Boehringer Ingelheim Vetmedica GmbH, used under license. ©2023 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-PET-0537-2023-B**
PRJ-00009765_0809_02_Senvelgo_AAHA_Full Page_NOV_8.375x10.875.indd   2

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Monitoring of cats receiving SENVELGO:
The veterinarian should re-evaluate the cat with a full physical examination and updated history to ensure the cat still solution should be given at approximately the same time every day. If a dose is missed, it should be given as soon promptly treat with insulin, even if blood glucose is normal.

Dosing instructions:
The SENVELGO dose is 0.45 mg/kg of body weight (1 mg/kg), once daily regardless of blood glucose level. The dose may be administered directly into the mouth or with a small amount of wet food. Do not mix into food.

Prior to initiation of treatment:
Prior to initiation of SENVELGO, the veterinarian should monitor for concurrent disease including pancreatitis, infectious disease, urinary tract infection, and concurrent hypersomatotropism (1).

Pharmacokinetics:
Maximum observed plasma concentration (Cmax), and by 45% for the mean area under the plasma concentration versus time curve (AUC) from dosing (time 0) to the last quantifiable concentration (AUC0-last), respectively.

Precautions:
Consider temporarily discontinuing SENVELGO during times of decreased caloric intake, such as surgery or decreased appetite, as continued administration of SENVELGO may increase the risk of diabetic ketoacidosis.

Adverse reactions:
Two hundred fifty-two (252) cats with diabetes mellitus were enrolled in a 180-day multicenter field study. Safety data were evaluated in 252 cats treated with at least one dose of SENVELGO. Regardless of blood glucose level, cats received SENVELGO at a dose of 0.43 mg/kg once daily. The most common adverse reactions were diarrhea or loose stool, weight loss, vomiting, polyuria, polydipsia, and elevated blood uric acid (BU). The table below summarizes the adverse reactions reported in the study.
WARNING: DIABETIC KETOACIDOSIS/EUGLYCEMIC DIABETIC KETOACIDOSIS

SENVELGO® (velagliflozin oral solution) equal to velagliflozin L-proline H2O 20.051 mg/mL, is a clear, colorless solution. Its molecular formula is C28H36N2O8, and its structural formula is:

\[
\text{C5H9NO2} \times \text{H2O}
\]

Monitoring of cats receiving SENVELGO:

- Increased risk of developing diabetic ketoacidosis.

Animal Safety Warnings

Prior to initiation of treatment:

- Clean and dry the area where the solution is to be administered.
- The solution should be given at approximately the same time every day. If a dose is missed, it should be given as soon as possible.

Dosage and Administration:

- During ongoing treatment with SENVELGO, blood glucose, fructosamine, urinary ketones, serum chemistry, body weight, and body condition should be monitored.
- Cats treated with SENVELGO may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis.
- Due to the risk of developing diabetic ketoacidosis or euglycemic diabetic ketoacidosis, do not use SENVELGO in cats with diabetes mellitus who have previously been treated with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of SENVELGO, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death.
- Contraindications:
  - Do not use SENVELGO in cats with diabetes mellitus who have previously been treated with insulin.
  - The safety and effectiveness of SENVELGO in breeding, pregnant, and lactating cats has not been evaluated.

The following adverse reactions were seen in the study with < 1% frequency: elevated creatine kinase >3XULN, hypercalcemia, anemia, abnormal behavior, bradycardia, and dermatitis.

Ketoacidosis and diabetics in cats:

Thirty-eight enrolled cats had been previously treated with insulin. Of those 38 cats, 12 (32%) developed ketoacidosis and 26 (68%) did not.

Dosage instructions:

- Cats should be screened for urinary tract infections and treated, if indicated, when initiating SENVELGO. Cats received SENVELGO compared to control cats. None of the cats showed any clinical signs of anemia and the number of erythrocytes, hemoglobin, and hematocrit values were normal. There was no effect of SENVELGO on white blood cells and platelets.

Adverse reactions:

- There were drug-related increases in rectal temperature, mean corpuscular hemoglobin, mean corpuscular volume, and HbA1C body percentage, and a decrease in mean corpuscular hemoglobin concentration in the cats that received SENVELGO compared to control cats. None of the cats showed any clinical signs of anemia and the number of erythrocytes, hemoglobin, and hematocrit values were normal. There was no effect of SENVELGO on white blood cells and platelets.

In a well-controlled laboratory margin of safety study in healthy, adult cats (see Target Animal Safety), after repeat daily oral dosing for six months, a slight to moderate increase in exposure to velagliflozin was observed. In addition, a tendency for a less dose proportional increase of maximum plasma concentration (Cmax) and exposure (AUC) over the tested dose range was noted.

Following oral administration of SENVELGO in cats at 1 mg/kg, velagliflozin was rapidly absorbed with a median time to maximum concentration of 0.29 hours. The elimination half-life of velagliflozin was 3.68 hours.

Effective use of SENVELGO was demonstrated in a 180-day multicenter field study. The cats included various purebreds and mixed breed cats ranging in age from 4-18 years and in weight from 5.7 to 26.5 lbs (2.6-12 kg). Cats were administered SENVELGO at 0.45 mg/kg (1 mg/lb) orally, once daily, regardless of blood glucose level, beginning on Day 0. Cats were evaluated on Days 2 or 3, Days 7 and 30 and then monthly.

Treatment success was evaluated on Day 30 and was defined as improvement in at least one clinical sign of diabetes mellitus (polyuria, polydipsia, inappropriately weight loss, hyperglycemia, or diuretic polyuria) and improvement in at least one blood glucose variable (blood glucose curve mean or serum fructosamine).

In 198 cats included in the effectiveness-evaluating population:

- 175 cats (84.4%) were considered a treatment success on Day 30 (lower bound of the two-sided 90% confidence interval was 84%).
- Mean blood glucose decreased from 444.4 mg/dl (single fastest sample) prior to Day 0 to 198.8 mg/dl (blood glucose curve mean) on Day 30.
- Mean fructosamine levels decreased from 551.4 μmol/L prior to Day 0 to 332.0 μmol/L on Day 30.
- Improvements in the clinical signs of polyuria, polydipsia, body weight, and polyuria, and diuretic polyuria on Day 30 were observed in 125/177 (71%), 128/176 (73%), 133/167 (80%), 33/80 (41%), and 73/30 (23%), respectively.

157 cats completed the 180-day study.

Target Animal Safety: In a well-controlled laboratory margin of safety study, SENVELGO was administered orally to fasted, healthy, 8 to 9 month old cats at 0.1, 0.3, or 5 mg/kg body weight (corresponding to 1X, 3X or 5X the human pediatric dose of 0.005 mg/lb) once daily for 26 weeks (6 months). Control cats (0 mg/kg) received saline at a volume equal to the 5 mg/kg dose. There were eight cats per group (4 females, 4 males). All cats survived the study and there were no SENVELGO-related effects on ophthalmic examinations, indirect ophthalmic blood pressure measurements, and blood cell counts. Hypertension, hyperbilirubinemia, hyperglycemia, hyperlipidemia, hypoalbuminemia, and weight gain were lower in the 5X group cats compared to cats in the control, 1X and 3X groups.

There were drug-related increases in rectal temperature, mean corpuscular hemoglobin, mean corpuscular volume, and HbA1C body percentage, and a decrease in mean corpuscular hemoglobin concentration in the cats that received SENVELGO compared to control cats. None of the cats showed any clinical signs of anemia and the number of erythrocytes, hemoglobin, and hematocrit values were normal. There was no effect of SENVELGO on white blood cells and platelets.

There were drug-related increases in serum magnesium, albumin, cholesterol, and triglycerides in the cats that received SENVELGO, with some magnesium, serum albumin and triglycerides above the reference range. There was a drug-related decrease in mean BUN in the cats that received SENVELGO. There were no other treatment-related changes to serum chemistry parameters, including serum glucose and symmetric dimethylarginine (SDMA).

A reticular pattern was observed on the surface of the liver of one control cat, three 1X, four 3X, and three 5X group cats.

How Supplied:

- SENVELGO (velagliflozin oral solution) 15 mg/mL, 30 mL nominal fill volume is supplied in a 45 mL plastic bottle with dosing syringe.
- NDC 100-4614-01
- Storage Information: SENVELGO can be stored at or below 77°F (25°C) with excursions permitted up to 84°F (29°C). Once the bottle is opened, use the contents within six months. Approved by FDA under NADA # 141-568.

Marketed by:

Boehringer Ingelheim Animal Health USA Inc.
Dubuque, IA 52003

SENVELGO® and SENVELGO Logo® are registered trademarks of Boehringer Ingelheim Vetmedica GmbH, used under license.

© 2023 Boehringer Ingelheim Animal Health USA Inc. All rights reserved. US-PET-0531-2023 Revised 06/2023

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>Frequency (N=22)</th>
<th>Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death and euthanasia</td>
<td>Nineteen cats died (30%) or were euthanized (16%) during the study, or shortly following removal from the study, with thirteen possibly related to SENVELGO use or declining glycemic control.</td>
<td></td>
</tr>
<tr>
<td>In total, 35 cats</td>
<td>were considered a treatment success on Day 30 and were defined as improvement in at least one clinical sign of diabetes mellitus (polyuria, polydipsia, inappropriately weight loss, hyperglycemia, or diuretic polyuria) and improvement in at least one blood glucose variable (blood glucose curve mean or serum fructosamine).</td>
<td></td>
</tr>
<tr>
<td>Dosage instructions:</td>
<td>Cats should be screened for urinary tract infections and treated, if indicated, when initiating SENVELGO. Cats received SENVELGO compared to control cats. None of the cats showed any clinical signs of anemia and the number of erythrocytes, hemoglobin, and hematocrit values were normal. There was no effect of SENVELGO on white blood cells and platelets.</td>
<td></td>
</tr>
<tr>
<td>Adverse reactions:</td>
<td>There were drug-related increases in rectal temperature, mean corpuscular hemoglobin, mean corpuscular volume, and HbA1C body percentage, and a decrease in mean corpuscular hemoglobin concentration in the cats that received SENVELGO compared to control cats. None of the cats showed any clinical signs of anemia and the number of erythrocytes, hemoglobin, and hematocrit values were normal. There was no effect of SENVELGO on white blood cells and platelets.</td>
<td></td>
</tr>
<tr>
<td>How Supplied:</td>
<td>SENVELGO (velagliflozin oral solution) 15 mg/mL, 30 mL nominal fill volume is supplied in a 45 mL plastic bottle with dosing syringe.</td>
<td></td>
</tr>
<tr>
<td>Storage Information:</td>
<td>SENVELGO can be stored at or below 77°F (25°C) with excursions permitted up to 84°F (29°C). Once the bottle is opened, use the contents within six months. Approved by FDA under NADA # 141-568.</td>
<td></td>
</tr>
<tr>
<td>Marketed by:</td>
<td>Boehringer Ingelheim Animal Health USA Inc. Dubuque, IA 52003</td>
<td></td>
</tr>
</tbody>
</table>
ATTENTION PRACTICE MANAGERS

SAVE 15% on MICROCHIPS with COUPON CODE AAHA15!*

Only $12.96 per microchip – includes prepaid, lifetime enrollment and collar tag

- Sold in 25 count boxes
- No Annual or Update Fees for your clients
- 24/7/365 live customer service

Free Auto Uploads from your Practice Management Software!

SAVE TIME
Go paperless with auto-uploads

SAVE MONEY
No additional enrollment costs

GIVING BACK
Proceeds support working K-9s and pet disaster relief

Let's Get Started! Call 800-252-7894 or visit www.akcreunite.org today!

*Shipping charges apply. Cannot be combined with other offers. Offer expires 1/31/2024.
Organize Inventory with Ease

5 Pro Tips for Making Managing Inventory Easier

by Nicole Clausen, CSSGB, CCFP
WHEN I FIRST STARTED MANAGING INVENTORY, my only training was, “When you shake a bottle and it feels low, order it.” I remember standing in the pharmacy thinking, “But wait, what does that actually mean?” In the beginning, I would walk around the pharmacy shaking bottles, digging through drawers, trying to remember all the products and supplies the practice kept in stock. Sometimes, I would forget to order something; other times, I wouldn’t order nearly enough; and other times, I would order way too much.

As I created systems as an inventory manager and eventually became an inventory consultant and educator for veterinary professionals, I’ve learned some tried-and-true methods and strategies that you can implement in your practice to make managing inventory much easier. What I’ve experienced over the years is that inventory management doesn’t have to be complicated and doesn’t need to take up a ton of time.

When we are managing inventory, we want to navigate the balance between two main goals. We want to have what we need in stock for our patients, all while keeping the financial performance of our practice in mind. Whether you are a beginner or a seasoned pro at managing inventory, here are five of my favorite strategies to make inventory easier and help you get back to your patients faster.

#1: Know What Items to Order and When to Order Them

In my experience, I’ve found that many practices keep track of what to order by using the “want book.” When something is running low, a team member will write it down in the book or on a whiteboard. Then, whenever it’s time to order, they’ll use what’s written down and walk around trying to identify any other low items. That’s the method I used when I first became an inventory manager.

As a beginner, I ran out of a few essential items because no one told me we were low and I had forgotten to check them. After that experience, I thought there had to be a better way, and I was on a mission to find it. That’s when I learned about reorder points and creating reorder flags that didn’t rely on the “want book.”

Reorder points are a flag to know when an item is running low; it’s the “point” or low level where an item should be ordered.

Reorder points are a great way to forecast your demand. It’s a way of using the data of what you’ve used or sold over a particular period to predict what you’ll use in the future. As an example, let’s say that for the last two
months, you’ve sold 4,000 capsules of gabapentin 100 mg. Knowing that information, you can predict that you’ll likely sell another 4,000 capsules in the next two months. Taking that information one step further, you can think about being “low” as having a two-week supply on the shelf, a commonly used reorder point. Rather than just shaking a bottle and guessing when it’s low, you’ll know precisely what “low” is.

A great way to get started with reorder points is with reorder tags. A reorder tag is a physical flag that’s attached to your reorder point. Then, when that reorder point is reached, a team member will take off the tag and stick it in a bin, and you know it’s time to order it. These physical tags work great for hospital supplies, consumables, bandaging supplies, janitorial supplies, and more. They are very versatile!

Let’s explore an example. You’ve determined that when you get down to three boxes of 1 cc syringes, you want to order six additional boxes. You would rubber band (or tape) the reorder tag to the third to last box. When someone opens that box, they remove the tag and put it in the “to be ordered” bin. Then, when it’s order day, you grab all the tags from the bin, and you know what to order.

The downside of using tags, though, is that your team might not put them in the bin. They might get put in the trash, on the shelf beside them, or ignored. That’s why I like to put bins throughout the practice, ensure the team knows exactly what to do with them, and develop fun ways to help your team get into the habit.

There are a few different ways of calculating reorder points and various types of reorder flags that you can use in your practice to help know when something is low without the “want book.”

If you’re already using reorder points in your practice, here are some considerations:

1. When was the last time you calculated your order points? Have you had any changes in your practice that might impact what you’re selling?
2. Are the order points you’re using now working for you? Are there any other types of flags you’d like to explore?
3. Are there any products in particular that you’ve run out of or would like to review the reorder points for?

Attach colorful reorder tags to inventory items and include details on when to reorder and how much to reorder.
#2: Invite Your Team to Get Involved
Inventory is a team sport! Although there might just be one or a few people ultimately responsible for inventory, the whole team can and should be involved. At the very least, everyone in the practice should recognize its importance to your patients and practice. Remember, having inventory in stock and accessible means we can care for our patients!

Depending on your practice, this could look like:
- Someone who loves craft projects might enjoy creating and maintaining reorder tags.
- Someone who loves organizing and watches *The Home Edit* on their day off might enjoy keeping the pharmacy, storage, and retail areas organized and tidy.
- A lead dental or surgery technician might be in charge of keeping the surgery suite or dental cart adequately stocked.
- Someone who loves spreadsheets, number crunching, and solving puzzles (with a dash of Type A personality) might enjoy being the inventory lead.

The benefit of cultivating a team culture that prioritizes inventory is that the patients win, whether the inventory team is responsible for it or the responsibility is shared throughout the practice. Also, having a team approach to inventory can bring added benefits. Different team members bring various skills and differing perspectives, there is shared accountability, and having a team approach can help catch errors more quickly and effectively.

#3: Leverage Your Practice Management System
Your practice management system or other inventory software can be an invaluable tool for your inventory. Depending on your software system, it can be a treasure trove of information and tools to make managing inventory easier. There are four main categories that I’ve found to be helpful:

**Reporting**
Depending on your practice management system, you can use different inventory reports to view sales reports and other financial information. For example, you can use sales reports to evaluate product markups and overall profit margins. You can also use reports to view the value of your inventory on hand to see if you’re overstocked, have excessive amounts of stock, or use them for accounting and tax purposes.

**Sales Information**
Even if you are not currently using the inventory module in your practice management system, you will likely still have sales information because of how practices invoice out clients. Using sales information can be helpful to see what products are selling, what your top items are, or what items might be on the shelf collecting dust. Using this information can help you make data-informed decisions for your inventory.
Inventory Tracking
When you use your practice management system to track your inventory, you’ll quickly see what you have on hand and what you are running low on. You can even use the difference between what’s on the shelf and what’s in the software to help catch missed charges, excessive waste, or theft. Remember our order points from tip #1? You can enter your reorder points into your software, and your software can flag when you are running low. Reorder points in your software and using reorder tags can be a winning combination to make managing inventory much easier!

Receiving
With many practice management software systems, you can receive or enter inventory after it’s been ordered and arrives in your practice. Using this function can help to easily update how much you’ve ordered (increasing your current quantity on hand) and update your prices as your costs increase. This workflow can help automate price increases so they don’t get missed and keep your inventory more accurate in your software.

Depending on your practice management system, it might have tools and functions to help manage inventory.

#4: Organize Your Inventory
Keeping your inventory organized can help you and your team find what they need, when they need it. Nothing is worse than having a critical case, digging through cabinets or drawers, and not finding what you need. Not only that, but creating a system for structure and organization in your pharmacy and practice can help reduce expired products, overordering, and products getting lost.

When organizing your inventory, I recommend that each item have a primary location (ideally with a label) and a defined secondary backstock or overstock location. This way, everyone on your team knows exactly where an item is located and can cut down on the mental labor of trying to remember where things are all the time.

You can also combine your shelf labels and reorder points to easily see your reorder points (and if something is running low). For example, you could have a shelf label for primary IV lines. The label could list the item name, code (for purchasing), the reorder point, and the reorder quantity. Then, as you’re looking through the pharmacy or central storage areas, you’ll be able to quickly identify where an item should be and whether it’s running low.

Organizing your inventory can be a great way to ensure everything can be found with ease and to know what you have on the shelf.
Cycle counting—counting small amounts of inventory frequently throughout the year—can make managing inventory much easier.

#5: Count Your Inventory

Cycle counting—counting small amounts of inventory frequently throughout the year—can make managing inventory much easier. You might be thinking, there is no way that I have enough time throughout the week to count inventory (and I don’t want to do this either!). I completely understand, but maybe I can help change your mind. Cycle counting is where you count small amounts of stock frequently, often weekly, throughout the year. With this process, typically, you count your high-value/often-sold items more regularly (like heartworm prevention or vaccines) than low-value/infrequently used items (like cotton balls or tongue depressors).

Cycle counting is helpful for several reasons. First and foremost, it helps you to keep your inventory in your practice management system accurate throughout the year. This means that your reorder points will flag at the appropriate time, and you can catch missed charges, theft, or other problems with your inventory. Additionally, because you kept your inventory accurate throughout the year, you don’t have to do a massive end-of-year count that takes days!

For example, it’s much easier to find out why you’re missing 187 cephalaxin capsules in one month than waiting until the end of the year when you realize you are missing 9,247!

Although cycle counts might not be the most fun task, they are very beneficial and help make managing inventory easier for you and your team.

Managing inventory doesn’t have to be a lonely and frustrating job. I know it can feel that way sometimes, but your role is valuable and vital to your practice. Whether you enjoy inventory or you’d rather be doing anything else, there are ways you can make managing inventory easier in your practice. I invite you to be curious about what might work for you, how you can implement these strategies, and how you can make a difference in your inventory. I’m cheering you on every step of the way! ✨

Nicole Clausen, CSSGB, CCFP, is the founder of Veterinary Care Logistics, a consulting and education firm specializing in inventory management for veterinary professionals. She is also the founder of the Veterinary Inventory Strategy Network, the host of the Inventory Nation Podcast, the creator of the Certified Veterinary Inventory Professional program (the first-ever certification for inventory managers), and the cofounder of Inventory Ally and is a regular speaker on inventory management.
Gastrointestinal Support formulas are indicated for dogs and cats with gastrointestinal disease.

- BLUE GI has been clinically proven to improve stool quality in both dogs and cats\(^1,2,3\)
- BLUE GI is approved for Growth and Maintenance in select formulas*
  *Canine GI Dry/Wet, Feline Wet
- BLUE GI features prebiotics and fermentable fibers to help support a healthy gut microbiome

Only BLUE offers the efficacy veterinarians demand with the ingredients your clients prefer to feed.

These guidelines were prepared by a task force of experts convened by the American Animal Hospital Association. This document is intended as a guideline only, not an AAHA standard of care. These guidelines and recommendations should not be construed as dictating an exclusive protocol, course of treatment, or procedure. Variations in practice may be warranted based on the needs of the individual patient, resources, and limitations unique to each individual practice setting. Evidence-guided support for specific recommendations has been cited whenever possible and appropriate. Other recommendations are based on practical clinical experience and a consensus of expert opinion. Further research is needed to document some of these recommendations. Drug approvals and labeling are current at the time of writing but may change over time. Because each case is different, veterinarians must base their decisions on the best available scientific evidence in conjunction with their own knowledge and experience.

The 2023 AAHA Management of Allergic Skin Diseases in Dogs and Cats Guidelines are generously supported by Hill’s Pet Nutrition, Merck Animal Health, and Zoetis.

This executive summary is not a replacement for reading the guidelines in their entirety. The full guidelines are published in the Nov/Dec 2023 issue of the Journal of the American Animal Hospital Association (jaaha.org) and available online at aaha.org/allergic-diseases.
Overview
THESE GUIDELINES PRESENT A SYSTEMATIC APPROACH to diagnosis, treatment, and management of allergic skin diseases in dogs and cats. The guidelines describe detailed diagnosis and treatment plans for flea allergy, food allergy, and atopy in dogs and for flea allergy, food allergy, and feline atopic skin syndrome in cats.

Management of the allergic patient entails a multimodal approach with frequent and ongoing communication with the client. Obtaining a comprehensive history is crucial for diagnosis and treatment of allergic skin diseases, and the guidelines describe key questions to ask when presented with allergic canine and feline patients. Once a detailed history is obtained, a physical examination should be performed, a minimum dermatologic database collected, and treatment for secondary infection, ectoparasites, and pruritus (where indicated) initiated.

The veterinary technician is an invaluable asset in dermatologic appointments. From taking comprehensive clinical histories to educating clients, technicians serve a vital role in the workup and successful management of pruritic patients.

The process of diagnosing and managing allergic skin disease can be prolonged and frustrating for clients. The guidelines offer recommendations and tips for client communication and when referral to a dermatologist should be considered to improve client satisfaction and optimize patient outcomes.

Introduction
An itchy pet is one of the most common reasons a client seeks veterinary care. Allergic skin diseases can cause discomfort and distress to the animal and stress to the pet’s family members.

Identifying the cause(s) of an allergic condition can be a long, often frustrating process for both clients and veterinary staff. Multiple follow-up visits may be required before a final diagnosis is achieved. With most of these patients, this is the start of a long journey, and clients should be informed that there are likely no quick fixes or cures, only lifetime management strategies. Patients with allergic skin disease often require lifelong management to optimize their quality of life.

To manage client expectations, prepare a realistic diagnosis and treatment plan that incorporates individual factors, including financial considerations.

These guidelines offer a step-by-step approach to diagnose and manage flea allergy, food allergy, and atopy in the dog and cat.
Prepare clients for long-term commitment and for the fact that occasional flares can occur in even the most well-managed patients.

Photographs, tables, algorithms, and flowcharts play a central, essential role in supporting the guidelines. These include photographs of pruritic patients and cytology to aid diagnosis, tables of recommended treatment options, decision trees, and a flowchart that illustrates the important contributions of technicians every step of the way.

Section-by-Section Summary
The guidelines are designed to simplify the path to diagnosis and management of canine and feline allergic skin diseases, while emphasizing a multimodal approach for the patient and effective client communication to ensure the best possible outcome. To that end, the guidelines are organized in eight sections, as summarized in the following. Each of the eight sections begins with three key takeaways. Because of space constraints, the key takeaways are not transcribed here. This is just one example of the guidelines’ usefulness and why it is necessary to read them in their entirety.

Section 1 describes the steps in diagnosing the canine patient with allergic skin disease. Each step in the process is discussed in some detail.

Step 1 is taking the clinical history and conducting the dermatologic physical examination. The guidelines offer a list of key questions to ask when taking the history and several photos of pruritic canine patients as a reference to aid in the physical examination (Figure 1). Step 2 is collecting the minimum dermatologic database; the minimum database is described.

Step 3 involves treating pruritus and step 4 is treatment for secondary infections and ectoparasites. The latter is supported by several images of the cytology of secondary bacterial and yeast infections (Figure 2). Step 5 is to recheck, verify medication, and assess response to treatment, with discussion of treatment options depending on the dog’s response to initial treatment. Step 6 is the diet trial, which is important to making a diagnosis because no historical or physical examination findings can differentiate atopy from food allergy. Figure 3 is a decision tree for assessing diet trial results.

Step 7 addresses seasonal atopy or nonseasonal atopy with seasonal fluctuation.

Section 2 addresses treating the allergic canine patient, with subsections devoted to flea allergy, food allergy, and atopy. The discussion of atopy addresses initial management as well as long-term management and acute flares.

Clients should be informed that there are likely no quick fixes or cures, only lifetime management strategies.
Atopic patients need lifelong medical care requiring routine veterinary visits and an active working relationship with the client. This stage can be frustrating as there is no one-size-fits-all treatment. Besides the need to manage secondary infections, inflammatory flares, and individual patient responses, veterinary teams must consider client compliance and finances.

Atopic patients need lifelong medical care requiring routine veterinary visits and an active working relationship with the client.

If adequate control of clinical signs cannot be achieved by the third veterinary visit, referral to a veterinary dermatologist should be presented as an option to provide more effective treatment and less cost in the long run.

Section 3 shifts focus to the feline patient, focusing on diagnosis. This section discusses clinical presentations of allergic dermatitis in cats and key differences between cats and dogs. Compared with dogs, the pathogenesis of allergic skin diseases in cats is not as well understood.

Feline atopic syndrome has been proposed as the umbrella nomenclature describing allergic dermatitis involving environmental allergens, food allergy (gastrointestinal manifestation), and allergic asthmas (respiratory disease) often associated with immunoglobulin E antibodies.

Feline atopic skin syndrome (FASS) refers to the entity associated with inflammatory and pruritic allergic skin disease from environmental allergens. The guidelines note that FASS can only be diagnosed based on compatible history and clinical signs and by ruling out all other similar-looking diseases.
None of the feline cutaneous reaction patterns are pathognomonic for any particular pruritic disease, emphasizing the need to perform a thorough diagnostic workup, including an accurate clinical history and dermatologic physical examination (step 1) and a minimum dermatologic database (step 2). The minimum dermatologic database should be collected based on reaction patterns (Figure 6).

Figure 5 presents photographs of the four distinct clinical patterns of feline allergic dermatitis: miliary dermatitis, head and neck pruritus, self-induced alopecia, and eosinophilic granuloma complex (including eosinophilic plaques, granulomas, and indolent ulcers).

Step 3 is to treat pruritus during the diagnostic period, and step 4 is to treat ectoparasites and secondary infections (a photograph shows superficial skin infection due to *Staphylococcus* spp.). Although topical antimicrobial therapies are ideal to reduce the overall exposure to systemic antibiotics, the grooming behavior of cats and their decreased tolerance for topical applications often limits their use.

Step 5 involves rechecking and assessing the cat’s response to antiparasitic/antipruritic therapies. Step 6 is the diet trial, referencing the algorithm in Figure 3 for assessing the trial.

Section 4 describes managing feline chronic allergic conditions, including initial and long-term management of feline allergic skin diseases and acute flares. This section addresses flea allergy, food allergy, and FASS.

Before launching into a discussion of treatment and management options, pause for a moment to congratulate the client for seeing the diagnosis process through. Doing so speaks volumes about a practice’s compassion and desire to cultivate long-lasting relationships.

The guidelines stress that ectoparasites and infections need to be ruled in or out before treating allergic skin disease. They also point out that FASS has different management considerations compared with canine atopic dermatitis; partnership with a veterinary dermatologist can be beneficial.
Section 5 provides an overview of diagnosis and treatment of allergic otitis externa (AOE) in dogs and cats, including clinical presentation, diagnosis, treatment, and short-term and long-term management. The guidelines note that AOE is an inflammatory condition and should not be confused with infection, though infection often occurs secondary to AOE.

Section 6 presents spectrum of care (SOC) considerations for allergic pets. Spectrum of care means providing a continuum of acceptable care that considers evidence-based medicine while remaining responsive to client expectations and financial limitations.

This section discusses SOC considerations relevant to the clinical history, physical examination, treatment, referral, and telehealth.

Section 7 discusses the vital role of veterinary technicians and how to optimize their involvement, as illustrated in Figure 7. A veterinarian working with two technicians can see two appointments in the time it would otherwise take to see one.

The only limiting factors are state regulations and a veterinarian’s willingness to train technicians to take over specific duties within defined parameters.

Many technicians want more responsibility commensurate with their training and allowing them to assume additional job duties is a wise investment of time for veterinarians.

Section 8 addresses client communication, with special emphasis on preparing clients for the long road ahead. This includes openly discussing factors like work schedules, household environment, and financial concerns that may affect patient care plans. It is especially important to manage client expectations, including that diagnosing and finding the right combination of treatments may take some time, that managing allergies is a lifelong commitment, and that flares occur even in well-managed cases. Ten key messaging points are offered.

The 2023 AAHA Management of Allergic Skin Diseases in Dogs and Cats Guidelines are a rich resource of information, tips, and recommendations written by a task force of experts. Owing to space considerations, this executive summary can provide only a high-level overview of the guidelines’ content. As mentioned previously, there is no substitute for reading the guidelines in their entirety. Access the full guidelines and additional resources at aaha.org/allergic-diseases.

The 2023 AAHA Management of Allergic Skin Diseases Guidelines are generously supported by Hill’s Pet Nutrition Inc., Merck, and Zoetis.

Constance Hardesty is a freelance writer living in Colorado. She is former editor-in-chief of AAHA.
Money Matters

Profit Checkup: What Are You Missing?

Check in with Your Finances in Advance of the New Year

by Karen E. Felsted, CPA, MS, DVM, CVPM, CVA

As we move toward the end of the year, it’s a good time to start thinking about the financial health of your practice and what changes you want to make for 2024.

Clean Up Your Numbers
Veterinary teams take great pains to make sure the results they get from diagnostic testing are accurate; if they aren’t, then any subsequent decisions made about the pet’s care won’t be right either. The concept is the same with management analysis. The result of any kind of analysis, including the profit calculation that follows, is only going to be as good as the quality of the data that went into it: garbage in = garbage out. If you’re not sure you have good quality input, here are some of the things to look for.

Check up with your accountant or a veterinary financial advisor to make sure you are recording transactions properly. One of the most common errors in practice financial statements is how payroll is recorded. Payroll is often incorrectly recorded on a “net” basis rather than a “gross” basis, and this will totally distort any analysis you try to do regarding compensation and benefits. Gross payroll is the full amount an employee earns; for example, 80 hours X $20/hour = $1,600.

Net payroll is the bottom-line amount actually paid the employee on their check after taxes, benefits, and other deductions are made. The
employee with a gross payroll of $1,600 may only receive $1,032 after taxes and their share of benefits are deducted. Obviously, if you look at total net payroll as a percentage of gross revenue, it may look like your practice has significantly less payroll expense than other practices, when in fact your payroll expense may be similar to or much higher than other practices if you had only been looking at the right numbers!

Other common mistakes seen in a practice profit and loss statement include treating loan principle payments or shareholder dividends as an expense and not consistently using the same categories for the same kinds of expenses. This consistency is important; for example, if a practice started out by recording the purchase of pet food in the “Drugs and Medical Supplies” expense account and then later switched it to the “Dietary Product” expense account, then these numbers will not be comparable before and after the change and the trends analysis and related conclusions may be inaccurate.

In order to achieve this comparability, it is important to carefully set up the accounting system and define calculations precisely. Sometimes it will be necessary for a change to be made in order to improve the accounting system. This is acceptable; just remember that in the month of the change, some comparability will be lost. This comparability will be regained as time goes on and more data is added.

Make Your P&L Easy to Read and Easy to Use
The profit and loss (P&L) statement is meant to be a summary document. It should give you a high-level overview of how well the practice is doing from a revenue and expense perspective. It is not meant to include every possible piece of information ever needed for the analysis of the practice.

In order to compare the practice with outside benchmarking studies and to get the most meaningful analysis internally, the accounts used in the P&L should be those generally used by the veterinary profession. An excellent source is the American Animal Hospital Association/Veterinary Study Group’s Chart of Accounts designed specifically for veterinary practices. This publication includes descriptions of the specific accounts and the types of transactions that should be recorded in each.

Very few practices will need every account included in this list; however, this Chart of Accounts is an excellent starting point. Ask yourself if particular info really has to be broken out in detail on the P&L before including it. For example, is it essential to have all 40 of the revenue categories on your P&L? No! A revenue by category report is readily available in every practice management information system when needed, so just use three to four revenue categories on the P&L. (Remember: it’s meant to be a summary!)

The same concept applies to expenses. Travel expense is a very small expense in almost every practice. It makes much more sense to have just one account (travel and lodging expense) for the expenditures rather than breaking them out into air fare, lodging, parking, transportation, tolls, and so on. If you ever need that level of detail, it is readily accessible from your accounting software.

The profit and loss statement shouldn’t be more than one or one-and-a-half pages long and should show expenses grouped into sections by type. Common sections include cost of goods sold/cost of professional services, compensation and benefits, revenue collection costs, facility and equipment expense, administrative expense, and other income/expense.
Anything longer or more complex than what is described here will make it impossible to get a good quality, high-level understanding of how the practice is doing. The point of the P&L will be lost.

**Profit Calculation**

There are many data points that could be reviewed to actually assess the financial health of your practice, but the most important starting point is the practice’s operating profit margin. This figure represents the gold standard measure of a practice’s financial success, and profits are a significant driver of cash flow and practice value. Unfortunately, most practices don’t really know how profitable they are. The only bottom-line number they look at is their net income, and this is not the same; in fact, net income can be very different from true operating profit and lead the management team down the wrong road.

The operating profit is the difference between the operating revenues and expenses of a practice. Operating revenue and expenses include only items normally and necessarily seen in the day-to-day operations of the practice such as fees for professional services and drugs and medical supplies expense. These items should be stated at fair market value rates. For ease of comparison with other practices, the profit margin is generally stated as a percentage—this is calculated as practice profits divided by gross revenue. Some of the items that must be calculated differently to determine operating profit versus taxable income or net income include practice owner payments, facility and equipment rent (if these items are owned by the practice owner and leased to the practice), services provided by family members to the practice, and personal expenses paid by the practice. Additionally, items such as depreciation, amortization, interest expense, and interest income are removed entirely from the calculation of profit, although they would appropriately be included in a net income or taxable income calculation.

Note, the term “EBITDA” or “adjusted EBITDA” is also used regularly and represents a very similar concept. EBITDA is an accounting term that stands for “earnings before interest, taxes, depreciation, and amortization.” The same adjustments that are made to calculate profitability must be made to determine a meaningful EBITDA number. An EBITDA calculation made without adjustments is pointless. The one difference often seen between an adjusted EBITDA number and an operating profit figure is related to equipment purchase. An operating profit calculation generally includes a deduction for average annual equipment purchase, whereas an EBITDA calculation does not.

Calculating the true operating profits of a practice is not a simple task, but an excellent resource to get you started is a booklet titled “The No-Lo Practice: Avoiding a Practice Worth Less,” available from vetpartners.org/practice-valuation-resources. VetPartners is a professional association of various kinds of business consultants and advisors who regularly work with veterinary practices. A veterinary financial consultant can also help you calculate this figure or refine your initial calculation.

**Using the Data**

If the practice’s profits aren’t at the desired level, what can be done about it? A lack of profitability comes from revenues that are too low, expenses that are too high, or a combination of the two. Understanding not only the profitability of the practice but the kinds of factors that lead to this state is critical. Until the practice has an idea of the root causes of the problem, it is difficult to determine what the correct solution is.
A lack of profitability comes from revenues that are too low, expenses that are too high, or a combination of the two.

Just looking at one data point, such as total revenue for a particular year, is usually not very helpful. The following types of data comparisons are most commonly seen and offer greater insights, including comparisons between practices or from one period to the next:

- Trends analysis within a particular practice (for example, a particular month is compared to the prior month or the same month in the previous year)
- Comparison of the practice’s metrics to published studies of these metrics within the veterinary industry
- Ratio analysis (for example, an expense is calculated as a percentage of total gross revenue)
- Analysis on a full-time-equivalent doctor or nondoctor staff basis
- Comparison of budgeted numbers with actual results

No comparisons are perfect; for example, activity in the practice may be cyclical and comparison of one period with another may show changes related to normal cyclicality rather than any improvements the practice has put in place. Different numbers of workdays in one period versus another can also impact the comparison. Regardless, internal trending is very helpful in understanding how well the practice is doing.

Key factors to consider when performing comparisons to published data include:

- How old is the data?
- Is the data meant to represent an average practice or “best practices”?
- Is the data reliable?
- Are the figures in the study calculated in the same fashion as in the practice?

No study will be perfectly comparable to all practices, but it is still possible to get valuable information to help operate the business more effectively. It simply means these comparisons must be used with caution and as one tool in running the business, not as the final word about how well a practice is doing.

Once the causes of a problem have been determined, specific action must be decided upon to correct a trend or improve operations. Finally, a practice should perform follow-up analysis to ensure the action decided upon is actually occurring and having the desired effect.

There are many outstanding management resources available to practitioners from organizations such as AAHA (aaha.org), VetPartners (vetpartners.org), the AVMA (avma.org), and the American Association of Feline Practitioners (AAFP) (catvets.com). Working with a financial advisor or practice consultant may help in not only gaining a greater understanding of the issues impacting profitability but in identifying and implementing solutions. VetPartners can help in locating an appropriate individual. Many continuing education events and veterinary publications also cover management topics that are useful in improving profitability. ★

Karen E. Felsted, CPA, MS, CVPM, is owner of PantheraT, a management consulting firm that works exclusively with veterinary practices and with companies in the animal health world that provide pharmaceuticals, dietary products, and business services to veterinary practices.
If veterinary businesses don’t need to provide clients with endless selection, and if they don’t need to stock every product that teams might ever need or want, then what is the purpose of retail inventory?

As the end of the year approaches, it’s time to do more than just count tablets, reconcile your count with your computer records, and pledge to track things better next year. Now is the time to rethink what you have on your hospital shelves, and whether that is consistent with your strategies for hospital success and customer service. You may be surprised to learn that you and your clients might be better served by considering other options.

Dispensing (including prescription medications, nonprescription over-the-counter products, and therapeutic diets) has long been a solid revenue generator for veterinary practices, typically accounting for 25–30% of income in primary-care hospitals. This makes dispensing the largest revenue source in most veterinary practices, but sadly, not necessarily the most profitable. If the veterinary pharmacy allows practices to deliver the level of care to which they aspire, clients benefit from the customized advice and instructions from the veterinary team. And if dispensing revenue can contribute to hospital profitability, then it makes sense to consider all your options.

The Purpose of Retail Inventory
In a bygone era (not that long ago, really), veterinary teams stocked the shelves with products that were...
required to meet medical needs and also products that they thought clients would want to buy, and that individual team members wanted to dispense. At a time when the profession had a relative monopoly on healthcare products sold for pets, this might have even made sense. However, times have changed.

Retail human pharmacies maintain a large inventory because they need to be responsive to physicians who could potentially write prescriptions for a variety of products and have them filled at the pharmacy of the patient’s choice. Big box retailers maintain a large inventory because they need to be responsive to the fact that customers appreciate variety in the products they select. This really isn’t true for veterinary practices, however. Clients rarely have the opportunity to browse for products in veterinary clinics, and there is no need to be a repository for every pharmaceutical that a veterinarian may ever choose to prescribe, so there is an opportunity for veterinary practices to be very selective as to what they choose to stock.

Of course, there is a difference between products that need to be stocked for internal use or to be dispensed and those products that might be prescribed or recommended, but may actually be provided more efficiently by others (e.g., partner pharmacies). Inventory occupies expensive real estate within a veterinary clinic, so it pays to be selective; there should be a compelling reason for each product to take up space on the shelf.

If veterinary businesses don’t need to provide clients with endless selection, and if they don’t need to stock every product that teams might ever need or want, then what is the purpose of retail inventory? Pharmacy items that become part of retail inventory need to serve a purpose, and that has both medical and business implications. Products stocked need to be medically relevant, and they need to be profitable for the hospital while still being competitively priced for the consumer. How does your inventory measure up?

It’s easy to misclassify products as being profitable if one only looks at revenue generation, but this is deceptive. Profit is what is left over after all the costs of inventory have been considered, including the direct cost of acquisition; indirect costs associated with ordering, receiving, and “carrying” products; the money tied up in inventory that could have been used for other purposes (opportunity cost); any commission (production) paid; and the wasteful cost of “shrinkage,” in which product was purchased and no longer available for sale, but for which no revenue was generated (e.g., theft, didn’t appear on invoice, and so on).

Even though veterinary clinics have a relatively small retail footprint, in most cases they are still carrying many more products than make sense from a business standpoint. In fact, most hospitals could cut in half the number of products they are carrying, and it would streamline their operation and potentially be more, not less, profitable.

As we approach year-end, look at your inventory critically, and decide whether each item you intend to restock in the new year meets the following criteria for inclusion:

- Products dispensed should reflect a hospital’s standard of care, and should be labeled for use in the species being treated.
- Products should promote client success at home, as convenience and compliance are important factors. Medications that don’t get administered as intended don’t benefit anyone.
- Products that have a unique competitive advantage for veterinary hospitals and that cannot be duplicated by other retailers (e.g., injectables) should be prioritized if medically prudent to do so.
Even though veterinary clinics have a relatively small retail footprint, in most cases they are still carrying many more products than make sense from a business standpoint.

- Products needing to be on hand for immediate medical use, even if not routinely used (e.g., emergency drugs), need to be managed and priced by different criteria than other inventory items. They warrant premium classification.
- Products should have predictable shelf-time between purchase and sale, so ordering and holding (carrying) costs can be effectively analyzed and managed.
- Preferred products should be profitable to dispense even when competitively priced for clients.
- Products stocked should promote healthy long-term vendor relationships, so inventory can be managed cost-effectively, while encouraging vendors to remain committed to your practice success and prioritize your business when the need arises (e.g., product shortages, stockouts, and so on).

Standards of Care

Standards of care can refer to many different things in clinical practice, but for the purposes of inventory selection and management, consider these standards to be consensus strategies as to the preferred way a given practice will approach common situations. Most standards of care are derived from guidelines that are produced by professional organizations, and AAHA has many such guidelines available for veterinary practices (aaha.org/guidelines).

The purpose of guidelines is not to create a cookie-cutter approach to medicine, but rather to provide an evidence-based roadmap around which team consensus can be built. From an inventory perspective, standards of care are important because there is often needless duplication of product categories within veterinary practices, and this affects the ability to provide products cost-effectively and profitably to clients. While every veterinary professional is bound to have their favorites in each category, choosing consensus products as first-choice options allows the hospital to secure the best purchase terms while reducing similar inventory items. It also lessens medical errors because hospital teams need to be familiar with fewer products.

This also allows practices to purchase larger volumes of prioritized products (rather than splitting the purchase across multiple products providing similar benefits), which often allows better pricing to the client. After all, is there really a need to keep six different parasite-control products on the shelf? Does it make sense to have three different benzoyl peroxide shampoos in stock? You might decide that the go-to nonsteroidal anti-inflammatory drug for your canine pain management standard is Product X, and that is the predominant such product on the shelf, but that still wouldn’t stop you from dispensing Product Y from your partner pharmacy if you thought it was more appropriate for a given patient.

Standards of care are not meant to stifle innovation or personalized medicine (pet-specific care). They are just a recognition of what the practice hopes to accomplish in the routine management of common clinical situations. Building consensus of entire hospital teams around standards also allows the practice to consider which products that are medically acceptable also make sense to stock from a business perspective. Even if it is a very good product, if it doesn’t meet the criteria established in the last section, it probably hasn’t earned a place on your product shelves. That doesn’t mean it can’t be dispensed from your
partner pharmacy, only that it doesn’t make financial sense to stock it in your in-house pharmacy.

**Product, Price, and Profitability**

When it comes to product selection, it is important to keep in mind that one of the features of a suitable product to be stocked in a veterinary hospital is that it needs to be sold at a price that is at least comparable with other retail channels available to them, while still being profitable for the hospital to maintain in inventory and sell. This can be challenging and must be evaluated for each individual potential product meeting the hospital’s standard of care.

When it comes to products for which veterinarians have a competitive advantage (e.g., injectables) it is much easier to prioritize them within standards of care, and there is more leeway in pricing that can be acceptable to both veterinary practices and consumers. In fact, if injectables are appropriate therapies in some situations, there are distinct advantages for the profession, because they are not going to be available through most other retail outlets that don’t have veterinary professionals or paraprofessionals able to administer them.

For many other dispensed items, the veterinary team may need to decide whether it makes sense to stock certain items in the hospital pharmacy or dispense them through a partner pharmacy. In a very simplistic sense, it may at first seem like it is worth stocking more products simply because they generate revenue, but unless costs can be effectively managed, such items can detract from practice profitability. Revenue numbers can be misleading because they don’t consider the indirect costs associated with inventory, which can be substantial. Certain items may be more profitable for the hospital if a commission can be generated from a partner pharmacy without the need to incur inventory costs.

There are also many products that just don’t make sense to stock in an in-house pharmacy because they can’t be sold at a price point that is competitive with other channels. For example, human generic medications may be cheaper than similar veterinary-labeled medications, but it is typically not possible to sell them to clients at a comparable price to that of a human pharmacy. If certain veterinarians truly believe that extra-label drug use meets their standard of care, then clients would be better served getting a prescription and buying those heavily discounted items elsewhere. If our commitment is to delivering client value, we can often better serve pet owners’ needs with products licensed for use in the species being treated.

’Tis the time of year when thoughts often turn, begrudgingly, to inventory. This year, perhaps there is an opportunity to do more than just product counts. It’s worth considering what you would like your inventory to be able to do for you in the year ahead—and work toward that New Year’s resolution now. ※

*Note: Some of this material has been abstracted from Five-Minute Veterinary Practice Management Consult, 3rd Edition, and from Pet-Specific Care for the Veterinary Team.*

---

**Recommended Reading**


---

Lowell Ackerman, DVM, DACVD (Emoritus), MBA, MPA, CVA, MRCPVS, is an independent consultant, author, and lecturer and the editor-in-chief of *Five-Minute Veterinary Practice Management Consult*, and *Pet-Specific Care for the Veterinary Team*. Find him online at lowellackerman.com.
In My Experience

Is Propofol During Euthanasia Doing More Harm Than Good?

by Kathleen Cooney, DVM, CHPV, DACAW resident

As good as propofol has been as a pre-euthanasia anesthetic, times are changing. It’s possible that holding on to propofol’s use is slowing progress toward more modern euthanasia protocols, especially in hospitals trying to elevate patient care. Patients benefit when everything is done to keep the procedure free of pain and anxiety, and today, this is best facilitated by giving sedatives and anesthetics before intravenous (IV) catheter placement is attempted. Clients want their pet sleeping and pain-free in their final moments.¹ They also want the chance to remain with their pet during the entirety of the appointment. In a time when exceeding client expectations is the norm, perhaps a pre-euthanasia propofol fade-out is worth exploring.

Why Do We Use Propofol Before Euthanasia?

The search for the perfect smooth euthanasia procedure has been in the making for a long time. Many have sought to find the perfect euthanasia solution and/or something useful before the procedure to soften the effects of the drugs we use.² ³ Pentobarbital, the most common euthanasia solution here in the United States, is reliable by itself when properly dosed and is leveraged for a variety of species.⁴ It remains the gold standard for companion animals, and while good at achieving death, can generate active signs of death.

The main disadvantage of propofol is a big one. It must be injected into a vein.
In My Experience

(e.g., agonal breaths, vocalization, muscle tremors) that are unpleasant for clients and veterinary personnel to see.5, 6, 7, 8 The ideal scenario is a patient that succumbs quickly to the euthanasia solution, as if to welcome a permanent deep sleep with no evidence of knowing it’s even happening.

Propofol became available to veterinary medicine in the early 1990s and is a staple drug these days. We rely on it for smooth anesthetic induction for both short and long procedures. It is reliable and very recognizable. You see a syringe of white solution and know what it’s for. For decades now, veterinarians and technicians have used propofol as part of a two-step euthanasia process: administer propofol IV, then administer pentobarbital. Because propofol must be given into the vein, the animal patient is traditionally brought to the treatment area where the staff will place an indwelling IV catheter, then be returned to its owner for the procedure.

I was unable to track down exactly how propofol gained such popularity as a pre-euthanasia agent. I’m sure the quick anesthesia effects and desire by practitioners to reduce active signs of death during euthanasia made it attractive. In 2019, however, a study revealed that propofol before pentobarbital has minimal benefits in this regard. Its use does appear to reduce some perimortem muscle activity and patient vocalization during euthanasia, although it does not have much effect on agonal breathing.9, 10 Agonal breathing is a normal reflexive response during death and is difficult for both clients and staff to see when they aren’t prepared for it. The rate of pentobarbital administration may have something to do with that11 but was not included in the study.

The main perks, then, are that propofol renders a patient unconscious before pentobarbital is given. This unconsciousness removes the need for any further restraint, lessens the risk of dysphoria from pentobarbital, and reduces at least some active signs of death.12 Propofol also removes the starkness of death. I’ve heard many pet owners mention how difficult it was to see the “light” leave their awake pet’s eyes during euthanasia. Using propofol to induce that ultra-deep sleep is like a rehearsal for the death itself. Clients see their pet peaceful and pain-free in their final moments, no longer moving or responding to sounds. As we will see, other anesthetics do all this, too, and with no need for venous access.

The Opportunity for Something Better

The main disadvantage of propofol is a big one. It must be injected into a vein. Propofol is ineffective when given intramuscularly and will create significant tissue damage.13 Venous access in awake patients means restraint, and this usually means the patient will be separated from its owners for the trip back to the treatment area for IV catheter placement. Can we keep the benefits that propofol has and remove this disadvantage?

The AVMA noted in their euthanasia guidelines that presedation or anesthesia should be provided for patients whenever practicable.14 I’m...
on board with this 100%. What they didn’t exactly specify is when to give it. Since the goal is to reduce fear, anxiety, and stress (FAS) during euthanasia, it makes sense to provide an anesthetic well before any technical aspects of euthanasia begin, and by this, I mean restraint for IV access, clipping fur, and the euthanasia solution injection itself. We have other anesthetics like ketamine, tiletamine, and alfaxalone ready for intramuscular injection that require minimal restraint in canine and feline patients. Euthanasia techniques have also evolved in recent years so that venous access isn’t even necessary. Pentobarbital can be given in other areas of high perfusion in the body, allowing staff to avoid veins altogether which is advantageous when blood pressures are poor or veins hard to find.15

Avoiding the Treatment Area
The treatment area can be a scary place with all its sights, smells, and sounds. Non-propofol anesthetics like ketamine, tiletamine, or alfaxalone may be given to the patient in the examination/comfort room. The patient may be offered treats and other distractions while the drug combinations are given. Veterinary support staff can work together with the client in the room to safely give the anesthetics with the least amount of pain or anxiety to the patient. After the injection is complete, the patient spends time with the client, being supported and loved. Once they are sleeping, then the IV catheter is placed with the patient unaware. The goal is for them to succumb to sleep with minimal restraint and discomfort, in line with modern euthanasia practices.

If you think of it with the idea that the patient enters the comfort room alive, and will only leave it deceased, you are on the right track.

Animal Hospice & Palliative Care Certificate Program
The Animal Hospice & Palliative Care Certificate Program is an online continuing education course covering topics in animal hospice, palliative care, and the euthanasia experience. The program is presented by Kathleen Cooney, DVM, CHPV, DACAW resident. Learn more at: aaha.org/education/online-training/animal-hospice–palliative-care-certificate-program.

Read an interview with Kathleen Cooney, DVM, CHPV, DACAW resident, in this issue, on page 56.
and/or emotionally), so keeping them out of the treatment area is beneficial. Reducing stress includes keeping them in safe and familiar surroundings (one room, not two), and with fewer people.\textsuperscript{16, 17}

What makes propofol worth avoiding is the tendency or potential to default to the old way of doing things. Old way: Separate patient to treatment area, restrain, place IV catheter, return to client after stressful event. New way: Keep patient in the examination/comfort room, give intramuscular (or subcutaneous or oral) anesthetic drug combination, allow patient to fall asleep with owner, place IV catheter (or use the intraorgan method), and administer euthanasia.

The veterinary team will need to agree that reducing FAS during euthanasia is important and impart protocol upgrades accordingly. I have seen many hospitals improve morale and team wellbeing by making this simple switch. Propofol will still have its usefulness for short procedures and surgical induction, and if an IV catheter is already placed following catheter placement was once the pre-euthanasia anesthetic after IV administration, clients want and expect the act of giving pentobarbital. Euthanasia has evolved to be more than the act of giving pentobarbital. The patient’s wellbeing is related to the time leading up to death as much as the moment of death itself. When considering companion animal euthanasia, clients want and expect more for their pets. Propofol as a pre-euthanasia anesthetic after IV catheter placement was once the gold standard, but the new gold standard says the patient should be sedated or anesthetized beforehand and to keep the patient with the client for the duration. With new nonvenous techniques gaining traction too, requiring the propofol protocol like the old days may do more harm than good for patients, clients, and veterinary teams.

Closing Thoughts
Euthanasia has evolved to be more than the act of giving pentobarbital. The patient’s wellbeing is related to the time leading up to death as much as the moment of death itself. When considering companion animal euthanasia, clients want and expect more for their pets. Propofol as a pre-euthanasia anesthetic after IV catheter placement was once the gold standard, but the new gold standard says the patient should be sedated or anesthetized beforehand and to keep the patient with the client for the duration. With new nonvenous techniques gaining traction too, requiring the propofol protocol like the old days may do more harm than good for patients, clients, and veterinary teams.

References


Kathleen Cooney, DVM, CHPV, DACAW resident, is Senior Director of Medical Education for the Companion Animal Euthanasia Training Academy (CAETA). She is a well-known speaker, author, and researcher pertaining to all manner of euthanasia-related topics. Cooney can be reached at kathleen@caetainternational.com.
Are You a Resilient Leader?

by M. Carolyn Miller

If the “great resignation” taught us anything, it’s that people are tired. And the storms won’t abate, given rising costs and a looming recession. The antidote, leadership gurus say, is a new leadership competency, resilience or “Type R,” as authors Ama Marston and Stephanie Marston dubbed it in their book, *Type R: Transformative Resilience for Thriving in a Turbulent World*.

So, as a practice owner or manager, how do you build personal resilience and show your team how to do the same? Simultaneously, how do you create, or continue to build, a practice where staff want to come to work regardless of the darkening skies?

It begins by understanding what resilience is. The old definition of resilience was about grit and determination, clinical psychologist Steven Stein told the Society of Human Resources Management (SHRM) in “Why Resilient Executives are Better Leaders.” Not anymore. Now, it involves self-awareness and responsiveness to those around you.

Resilience has three levels of competence, each linked to the other, noted Deloitte Consulting, LLC, a global financial consulting firm, in “Turning Resilience into a Core Competency.” The first level is personal; that is, observing and commandeering your own thoughts.

The second level concerns your ability to connect and empathize with...
others. Has a staff member suddenly taken on additional caregiving responsibilities? Ask how you or the practice can support them. Did your partner recently have a health crisis? Express your concern.

The third level is about how you respond to outside forces. This can be the competition that has moved in down the street and demands an innovative response. It can also be your response to a virus that is spreading across the globe and demands new practice operational procedures.

**Personal Resilience**

Personal resilience is an inside job. It involves your ability to be aware of your thoughts, emotions, and reaction patterns and have agency over them, noted Deloitte. For instance, does a new practice challenge immediately cause you to feel victimized? And are you aware enough to see that and then redirect your thoughts more positively?

Another skill of personal resilience is your ability to be realistically optimistic. In other words, do you believe wholeheartedly that you can overcome whatever is ahead? And can you see the challenge, and your response to it, as your values in action? For instance, during the pandemic, did your practice rally to the challenge and come up with innovative ways to serve your clients and their pets because that is part of your mission?

**Interpersonal Resilience**

Connection and empathy matter in the workplace, noted Deloitte. And they are built via a “collection of moments” that can make or break communication. One of the biggest relationship builders is how you respond to an employee’s good news. If you applaud the person and even help them relive the experience by asking details, you build trust and empathy at a deep level.

Even “negative” interactions, such as how to address a staff member’s behavior, can build communication. It’s all a matter of attitude, noted Deloitte, moving from one of “reprimand” to one of “curiosity.” Listen rather than speak.

**Environmental Resilience**

Outside forces can be market-driven, such as rising supplier prices. They can also be larger social issues that prompt you to take a stand. And while you can’t control these forces, you can control how you respond to them and the meaning you attach to them. In other words, can you turn the obstacle into an opportunity for your practice, and its staff, to grow?

Environmental resilience also involves your impact and service to others. For those in the veterinary field, this is often second nature. And the pandemic revealed the level of dedication practices had toward serving their clients and patients in overcoming that particular environmental challenge.

These three layers are intricately woven together. And it is your ability to learn and model these competencies that will dictate your ability to thrive regardless of what’s ahead. In doing so, you will teach by example how your team can do the same.

Resilience Home Team

Begin by affirming your mutual goal. For instance, “Can we agree that the goal is for you and Sallie to be able to work together amicably?” Then, test your assumptions by asking questions. (And take responsibility for any way you or practice systems may have contributed to the issue.) Finally, conclude the conversation by agreeing on a next step.
Can Euthanasia Be Beautiful?

A Conversation with Kathleen Cooney, DVM, CHPV, DACAW resident

Interview by Katie Berlin, DVM

Have you ever known veterinary team members who seem to seek out euthanasia appointments? Maybe they even seem happier afterward? In general practice, end-of-life care can feel like a big downer, although it’s part of almost every day. But according to Kathleen Cooney, DVM, CHPV, DACAW resident, euthanasia can be the most beautiful part of the day for the veterinary team, and for some team members, seeing more end-of-life appointments is actually self-care.

In her second appearance on Central Line: The AAHA Podcast, Cooney explains that a large part of delivering that beautiful euthanasia experience is self-regulation on the part of the veterinary team, which also helps keep compassion fatigue at bay.

Kathy Cooney: There’s always an opportunity to make euthanasia beautiful, especially for our patient, because there may sometimes be emotional turmoil between the veterinary team and the client, but who’s ultimately at the end of that needle is our patient, and we have to do right by them. The animals pick up on the negative energy in the room, so I always call upon the veterinary team to relax themselves and self-regulate, to carry through with a technically sound, strong euthanasia appointment, even though they may be upset about things. It can still be done.

Whether it’s a veterinarian or a technician performing the procedure, once they’ve made the decision to move forward, they need to practice with principle-based medicine, not outcome-based medicine, meaning they are focused in on what they can control—and that is their principles, their values, and their virtues. Their kindness, their patience, their tolerance, their loving nature.
Now, that said, it’s important for veterinary teams to have euthanasia manuals, standard operating procedures, that the team agrees to. How do you define “convenience euthanasia” and what situations for euthanasia will we actually feel comfortable proceeding with? Get everybody on the same page, because there are few things more stressful to a team than when one veterinarian or technician will euthanize a patient because they think it’s right and another team member thinks it’s wrong.

Katie Berlin: It’s an important distinction—that we are not saying, “We will say yes or no to every convenience euthanasia, so we don’t have to argue.” We are saying, “This is how we handle it. These are the questions that we ask. This is how we speak to each other and the client.”

“Once judgment enters the conversation, it’s so hard to get it out of the room. In my experience, once we start to question and everybody’s talking, even when they’re not involved in the case, that’s when it feels like a crossroads; and as a team, it’s a time to come together.

Advocating for the Patient

KC: What I find is probably the hardest thing is when the client feels that it’s the right time for euthanasia, but the veterinarian is unsure. We really want to try this pain medication or change the diet, do something. And the fact that the client ultimately is the one who makes those decisions puts the veterinarian in a challenging spot, so it’s a matter of following what you think is best ethically and making sure, again, that we’re paying attention to the patient in front of us, because we can get so wrapped up in what’s going on with the client that we fail a bit to advocate what’s best for our patient.

So it is about being bold enough to go there and say, “If there was care available to improve quality of life and extend things for a period of time, how would you feel about that?” But knowing that when you open up the floor like that and all the client gives you is a negative, then more than likely they’re not going to be able to go down that path. And
then the veterinarian has to decide if euthanasia is going to be the best course of action. Because we know that suffering is coming. It may not be there to the extent where euthanasia is warranted today, but it is coming. So is it worthwhile to make that decision sooner rather than later?

It is always a leap of faith. We just don’t know truly how much more time this animal would have with or without palliative care sometimes, so it’s about making a leap of faith in the patient’s best interest, knowing that oftentimes it’s going to be in the client’s best interest as well.

**KB:** I saw a post once way back when, where I think somebody was struggling with this question, and one of the veterinarians who responded said something like, “There are many worse things for a pet than a good death.” I think about that a lot. In many cases, it’s not the best thing for the pet to go home with an owner who is determined that that pet be euthanized today and gets talked out of it. If they take the pet home, those are a lot of complicated emotions to send a person home with, and then here’s this animal that depends on them completely, and they have to rethink all of the feelings that they just came into the vet clinic with, and I just think that’s got to be really hard.

If I’ve made the decision to take my pet in for euthanasia, I’ve decided. It’s taken a lot of soul searching to get there and I’m not in a great position to rethink that.

**KC:** When a client’s made up their mind that they want euthanasia, for a veterinarian to change direction in that moment is asking a lot. It’s extremely challenging. And that’s where I often just need to focus in on my patient there and say, “Yep, I know everything that the client’s saying. I know that they had a goodbye farewell party last night. They’ve been posting pictures all over social media. Today is the day.” However, you might have a patient in front of you that says, “But what if I don’t want today to be the last day?”

I don’t know many things that are more challenging than that situation. So that’s where I at least like to open up the floor to give the family time to unload for five to ten minutes and tell me everything that I really need to hear to make sure that moving forward with euthanasia makes sense.

Whenever I start an appointment, I establish rapport with my clients for a good 5 to 15 minutes, so I can get more back story, because a lot of these clients I’ve never met before. This is the first time that I’m meeting their pet, and I need to know more of that back story besides what they just told me on the phone or my intake form.

Like so many others out there, I have dedicated my entire career to end-of-life and euthanasia in particular, and [once I] helped 10 pets in one day; I can get up the next day and be able to do it again because every single appointment I approached in the right manner.

**KB:** For somebody who really is doing the work for themselves and letting principles guide them, it seems like that could be a very, very satisfying day.

**Self-Care, Self-Aware**

**KC:** One of my favorite tips is for hospitals to place an image of the human-animal bond outside of the euthanasia room, whether it’s a traditional exam room or a euthanasia comfort room. The purpose of it is to take pause, to stop and look at it, and then just take a deep breath.
and relax your body before you walk into that room. It gets you in the right headspace to be fully present.

It’s actually a self-regulation exercise, which will calm you so that you have a better barrier against secondary traumatic stress and therefore against compassion fatigue. Compassion fatigue really is two things: burnout and secondary traumatic stress, also known as vicarious traumatization. It’s really hard to manage burnout, let’s face it, we’ve got a zillion things going on, and I think many of us would be burned out just with family life, independent of vet med.

But the secondary traumatic stress part, that is something we can be in control of—to relax our bodies so if we are witnessing the primary traumatic stress of the client or our patient, whatever trauma we’re witnessing, we are calm physically.

KB: At the hospitals where I’ve worked, there’s always been a technician or two who have prided themselves on being the one who’s tough. If somebody else is having a bad day, they’re going to go in and take care of the euthanasia, or they’re going to go in and take care of the sobbing client with the walk-in emergency, or nothing can ever really get to them. And I did worry a little bit sometimes that they would go in and it would feel callous to the client, because they were so adamant that nothing could reach them that they didn’t allow themselves to feel with the client and to put themselves in the client’s shoes and treat the client with the delicacy that most of us need in those situations.

But I also worry about them. I worry that they actually had a lot of feelings that were not getting acknowledged. How do you take care of team members who don’t seem to need to be taken care of?

KC: I think a really smart move is for management to ask personnel their feelings about euthanasia when they first hire on, about the volume of euthanasia they think that they can handle, because some are already self-aware enough to know that one euthanasia a day is about all that they can manage. Somebody might say, “I can handle as much euthanasia as you want to come my way,” and that’s then somebody that you need to track regularly because more likely they are taking on those euthanasia appointments.

In fact, part of what brought me into end-of-life as my career choice was the private practice that I was working at in Michigan right after graduation. I found that they were aligning me with...
a lot of the euthanasia appointments throughout the day, so I was actually performing more euthanasia than some of my colleagues. And I said, “What’s this all about?” And they said, “Well, you seem to do pretty well when you come out of those appointments. You seem balanced, like you’re better than when you went into the appointment.”

With regard to the techs and the veterinarians, if they want to go into those rooms because they want to have the story time and they want to see the connection, I think it’s important to let them do that, but [also] make sure that they’ve got the right skills in place to protect them from either primary or secondary traumatic stress. And if they’re the type of person that will feed on that bond and the beauty of euthanasia the right way, that may sustain them in vet med. So I never want anybody to gravitate away from it or to [say], “You can only do one or two euthanasias a day,” because it really might be their soulful work.

That said, if there is somebody who’s saying, “Yes, I want to take all the euthanasias to protect everybody else,” I think it’s a matter of really looking at that person and making sure that they’re not already exhibiting signs of compassion fatigue. Are they sarcastic? Are they snarky? Are they talking about escape fantasies? They shouldn’t be the ones who are going in there because it could actually make them worse. So anybody who’s got the skills in place emotionally, physically to be present for euthanasia, I am all for it, but it’s up to management.

KB: I definitely remember situations where we’ve said, “No, you’ve already had three today, like somebody else should take this one,” and we thought we were being protective, but it’s possible that that person really loved those appointments and didn’t really know how to say so, because in some places it’s not seen as something that you should want to do.

KC: Exactly.

The Spectrum of Feelings

KB: How, as a team, can you help each other deal with those feelings that linger after the appointment’s over?

KC: I’ll first say that it’s normal to feel a variety of emotions, and sometimes it’s conflict, sometimes it’s regret—it’s all over the board. What my approach has been is to leverage emotional intelligence in general. Knowing what your triggers and motivations are, why you feel the way you feel, even simple self-awareness: “What am I feeling right now?” Acknowledging what that emotion is and giving yourself a chance to unpack it and decide, “Do I want to feel this way? How do I want to feel and how do I get there?”

But part of the exercise of standing in front of that picture outside of the euthanasia room is to reflect on what’s on the other side of that door. Who am I bringing into that space and who am I interacting with? Is this a dog that looks just like a dog that I lost two months ago, or is it a little girl that looks just like my daughter? Recognize what those triggers are to get yourself in the right headspace before you go in, and also during. And one of my tips is always to take a lot of sighs and deep breaths during euthanasia, to continue to relax yourself during that interaction, so that when you walk out you are

“Compassion fatigue really is two things: burnout and secondary traumatic stress, also known as vicarious traumatization.”

—KATHLEEN COONEY, DVM, CHPV, DACAW RESIDENT
in theory more balanced and in a better headspace than you would have been had you not gone through those exercises.

But at the end of the day, we still have those appointments that stick with us a little more, so ask yourself, “Do I need to keep thinking about this? What is the goal of putting this energy into it?” And if it was because it was mildly traumatic, if it was mildly stressful, “How am I going to go into the next euthanasia and be more in control so that I can be, again, more resilient in this work?”

I like to listen to comedy radio. I love music. I love being able to compartmentalize to the best of my ability so that I can walk into the room with my euthanasia hat and my doctor hat on, and then I can take that off and be kind of my normal Kathy self. When I ride along with veterinary students from Colorado State University, they say, “Dr. Cooney, you are two different people. You got your game face on when you were in there with the family and you are calm and you are compassionate. You are so fully there in the moment.” And as soon as that client departs and I’ve got my patient who’s now deceased respectfully contained, ready for aftercare or whatever that it is, I am a completely different person. My voice changes, my attitude changes, and I’m my jovial self. So that is a very active approach, to just say, “I’m not going to let this sit with me all day,” and feel good about that helper’s high in the work that I just did.

**KB:** That is the first time I’ve ever heard anybody talk about that. The time when you come out of the euthanasia room and everybody expects you to be really serious and sad, and it almost seems like if you’re not feeling it really hard for a while afterward, then you are being callous or you didn’t care. But if you’re actually processing the feelings in that moment and, like you said, doing the work to make sure you’re in the right place when you go into that room and being present for every moment that you’re in that room, then you don’t necessarily have all of that weight when you come out. And like you said, you have a helper’s high. I just did my job really well.

**KC:** Yeah, I just did awesome work.

---

Also see a related article by Kathleen Cooney, DVM, CHPV, DACAW resident, in this issue on page 50.

Central Line: The AAHA Podcast is generously sponsored by CareCredit.

Catch the full episode, and every other episode of Central Line: The AAHA Podcast, on major podcast platforms, YouTube, and at aaha.org/podcast.
### Advertiser Index

<table>
<thead>
<tr>
<th>Advertiser</th>
<th>Page(s)</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAHA Store</td>
<td>63</td>
<td>aaha.org/store</td>
</tr>
<tr>
<td>AKC Reunite</td>
<td>28</td>
<td>akcreunite.org</td>
</tr>
<tr>
<td>Animal Arts Design Studios, Inc.</td>
<td>63</td>
<td>animalarts.com</td>
</tr>
<tr>
<td>Blue Buffalo</td>
<td>35</td>
<td>BLUEVetConnect.com</td>
</tr>
<tr>
<td>Boehringer Ingelheim Animal Health</td>
<td>6–8</td>
<td>NexGardPLUSClinic.com</td>
</tr>
<tr>
<td>Boehringer Ingelheim Animal Health</td>
<td>24–27</td>
<td>SENVELGOClinic.com</td>
</tr>
<tr>
<td>CareCredit</td>
<td>False</td>
<td>carecredit.com/vetenroll</td>
</tr>
<tr>
<td>CareCredit</td>
<td>Inside Back Cover</td>
<td>carecredit.com/vetinsights</td>
</tr>
<tr>
<td>CPAC Environmental Solutions</td>
<td>2</td>
<td>cpac.com</td>
</tr>
<tr>
<td>Euthabag</td>
<td>63</td>
<td>euthabag.com</td>
</tr>
<tr>
<td>Hill’s Pet Nutrition</td>
<td>3</td>
<td>hillpet.com/cat-food/pd-kd-feline-dry</td>
</tr>
<tr>
<td>The Medi-Dose Group</td>
<td>Inside Front Cover</td>
<td>MediDose.com</td>
</tr>
<tr>
<td>Merck Animal Health</td>
<td>18</td>
<td>usa.petdiabetesmonth.com</td>
</tr>
<tr>
<td>Midmark Corporation</td>
<td>1</td>
<td>midmark.com</td>
</tr>
<tr>
<td>Purina® Pro Plan® Veterinary Diets</td>
<td>Back Cover</td>
<td>purinaproplanvets.com/microbiome</td>
</tr>
</tbody>
</table>

*Trends magazine* is not responsible for contact information not specifically provided by an advertiser for use in the Advertiser Index or for other company contact information not listed in this index. Please contact the advertiser directly for all product information.
**AAHA Marketplace**

### ANIMAL ARTS

Authors of the comprehensive guide to *Veterinary Hospital Design*

**PRACTICAL GUIDE TO VETERINARY HOSPITAL DESIGN**

*From Renovations to New Builds*

40+ Years of expertise in animal care architecture and design

www.animalarts.com 303.444.4413

### EUTHABAG

Depart with dignity.

**THE NEW PRACTICE STANDARD**

Get your FREE EUTHABAG sample now

Get $25 OFF your first starter kit

### AAHA Controlled Substance Logs

With the new AAHA Controlled Substance Logs, you’ll enjoy peace of mind knowing that your practice is in full DEA compliance—and you’re providing greater efficiency and security for your staff. Thoroughly revised, redesigned, and reviewed by industry experts and former DEA officials to better serve your practice team.

**Shop today at aaha.org/store.**
Sadie McDonald, CVT
Veterinary Technician
Hawthorne Animal Hospital
Glen Carbon, Illinois

Year started in vet medicine: 2013
Years with practice: 6
Nominated by: Kelsie Reider

Why Is Sadie So Awesome?
Sadie is an excellent employee who gives 110% every shift. She is dependable and smart, has amazing tech skills, knows every aspect of the hospital, is responsible and reliable, puts her patient care first, and is able to think outside of the box. Sadie is an open door to talk to about all of the different responsibilities she has at Hawthorne.

How Does She Go Above and Beyond?
Sadie is always going the extra mile when taking care of the patients in the front and back of the hospital. She is always willing to step in and help when doctors need help. She is wonderful at communicating complicated diagnoses to clients in ways that help them better understand. She is always willing to stand up for coworkers when necessary. She knows all aspects of the hospital, which allows her to understand and empathize with coworkers in all departments.

In Their Own Words
Why do you love your job: I love that when I go home at the end of the day, I always feel like I made a difference. I also love that every day is different, and you never know what you are going to see or do when you come in to your shift.

Pets at home: I have a six-year-old mixed-breed dog named Tipsy.

What brought you to the profession: I started working as an animal care attendant when I was 19 and started to shadow surgeries over time. I fell in love with veterinary medicine after that.

Hobbies outside of work: I have a three-year-old and a one-year-old, with another on the way, so most of my time is spent running them around! I also enjoy reading and listening to true crime podcasts.

Favorite book/TV show: My favorite book is The Woman in the Window by A. J. Finn. My favorite show is You, and my favorite actor is Steve Howey.

Each month Trends spotlights an AAHA member, with generous support from CareCredit.* If you want to nominate someone, visit aaha.org/EOTM and enter them for a chance to win an Amazon gift card for you and your nominee!

*The Employee of the Month contest is administered by AAHA.
Flexible financing that helps pets get the care they need, while pet parents enjoy the ease of simple, convenient monthly payments. That’s the CareCredit experience. Call us today to get started 844-812-8111. And if you’re already enrolled, remind your clients that you offer this flexible financing option.

SIGN ME UP FOR delivering peace of mind.

YOU CAN LEARN MORE AT carecredit.com/vetinsights

CALL US TODAY TO GET STARTED 844-812-8111
TARGETED MICROBIOME SUPPORT FOR GI HEALTH AND BEYOND

A healthy microbiome can impact a pet’s overall health. That’s why we’ve spent decades exploring microbiome science. From diets with specific prebiotic fibers that support digestive health to supplements that support calm behavior, immune health, or dogs with diarrhea, we’re dedicated to helping you improve your patients’ lives in new ways.

LEARN MORE AT PURINAPROPLANVETS.COM/MICROBIOME

Purina trademarks are owned by Société des Produits Nestlé S.A.